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ABSTRACT
CHARACTERIZATION OF A MUTANT ONCOLYTIC ADENOVIRUS AND THE
ROLE OF JNK IN ENHANCING VIROTHERAPY
Stephen L. Wechman
February 8, 2017
Oncolytic adenoviruses (Ads) have great therapeutic potential for lung cancer
treatment. Cancer selective E1b-deleted Ads are safe; however, their clinical
cancer therapeutic efficacy remains limited. The limited efficacy of Ad virotherapy
is due to many factors including inefficient cancer cell lysis, Ad release and
spread. Progress in overcoming these barriers to Ad virotherapy are hampered
by limited knowledge of the genes associated with enhanced Ad release and
spread and the dearth of understanding of the mechanisms by which E1bdeleted Ads cause cancer cell lysis. The role of c-JNK n- terminal kinase (JNK)
phosphorylation in this process remains unknown. By uncovering the molecular
aspects that enhance Ad spread and oncolysis, this dissertation has addressed
critical gaps in the oncolytic Ad field. In chapter II, the novel oncolytic Ad mutant,
AdUV, was developed. AdUV displayed enhanced oncolytic effects, release, and
spread in A549 cells. AdUV also induced autophagy more effectively than the
parental strain Ad5. In chapter III, AdUV was subjected to DNA sequence
analysis to determine which AdUV mutations may have induced these enhanced
cancer therapeutic effects (spread, Ad release, and oncolysis). For example,
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mutations to the DNA-binding genes 52K and pV may have enhanced AdUV
release. These mutations increased the number of encoded positively-charged
amino acids in AdUV. Therefore, I hypothesized that these mutations may have
increased AdUV’s binding affinity for the negatively-charged DNA sugarphosphate backbone. In chapter IV, the mechanism of Ad-induced JNK
phosphorylation was investigated to further characterize Ad oncolysis. These
data indicated that Ads induce p-JNK via the expression of E1b-19K and E1a.
Additionally, we have shown that the p-JNK inducer, etoposide, enhanced
oncolytic effects, but not the replication of AdUV in vitro. This work has advanced
the knowledge of Ad oncolysis and will lead to further progress in the field of
oncolytic virotherapy.
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CHAPTER I
GENERAL INTRODUCTION
1.1 – Lung cancer

Lung cancer is the leading cause of death from malignancy. The
number of lung cancer deaths (158,140) in 2016 was comparable to the
number of deaths (157,548) from the next four leading cancers combined:
colon, breast, pancreatic and prostate (American Cancer Society). The
Surveillance Epidemiology and End Results (SEER) statistics indicate that the
five-year survival rate of lung cancer patients improved from 11.4% in 1975 to
17.5% in 2006. However, lung cancer will continue to be a leading cause of
death from malignancy unless more effective treatments are developed.

Surgery remains the best treatment option for early stage (Stage I and
II) lung cancer. Most stage I and II lung tumors are minimally invasive,
therefore lobar resection is feasible for these patients. When primary lung
tumors are resected, 85% of stage I and 77% of stage II cancer patients
survive at least two years after diagnosis [1]. However, patient follow-up is
necessary to observe for recurrent primary or metastatic tumor growth
following resection. Surgically resected stage II lung cancer patients, but not
1

stage

I,

are

also

frequently

treated

with

adjuvant

platinum-based

chemotherapy [2].

For lung cancer patients with disease beyond stage II, the combination
of surgery, intravenous (IV) chemotherapy, and radiation provides the best
results [3-5]. Stage III lung tumors have regionally metastasized to the lymph
nodes and often have invaded at least one of the tissues surrounding the
lung, including the chest wall, pleura, or the main bronchus [6]. Stage IV lung
tumors can be of any size however, distant metastasis are observed [6].
These distant metastases are often observed in the adrenal glands, bone, the
opposite lung, liver or brain [7, 8]. The majority (57%) of lung cancer patients
have distant metastases at the time of diagnosis. Therefore, most lung cancer
patients are stage IV and are ineligible for surgery. Alternative treatments to
surgery such as cancer chemotherapy have not significantly enhanced lung
cancer patient survival despite the investigation of several different
chemotherapeutic combinations [9-11]. To treat lung cancer patients more
effectively, the development of novel cancer therapeutics is imperative.

1.2 – Oncolytic Virotherapy

The use of cancer selective viruses, or oncolytic virotherapy, is an
emerging lung cancer treatment option with great therapeutic potential [12,
13]. Oncolytic virotherapy is unique because these viruses can spread within
2

tumors following their initial infection of a small number of tumor cells [12, 14].
The cancer selective (oncolytic) adenovirus (Ad) dl1520 displayed favorable
safety and induced anti-tumor responses during preclinical and clinical studies
[15-17]. To date, two oncolytic viruses have been approved for the treatment
of cancer. First, a virus very similar to dl1520, H101, was commercially
approved in China for the treatment of head and neck cancers in combination
with the PF chemotherapy regimen (cisplatin and fluorouracil) by the China
Food and Drug Administration (CFDA) [18]. In a phase III trial, H101
increased the tumor response rate of head and neck cancer patients treated
with the PF regimen from 39.6% to 78.8% [19]. Secondly, the United States
Food and Drug Administration (FDA) approved the oncolytic herpes virus TVec, which expresses the immune stimulatory cytokine granulocyte
macrophage colony stimulation factor (GMCSF) for the treatment of malignant
melanoma [20]. Interestingly, both oncolytic virus replication and the
expression of GMCSF contributed to T-Vec’s cancer therapeutic efficacy [20].
Novel oncolytic Ads, such as ColoAd1, are also currently under investigation
in a phase II clinical trials and have shown great cancer therapeutic potential
[21]. Next generation ColoAd1 vectors feature Ad3/11 capsid chimeras which
were shown to have the greatest cancer therapeutic activity and stability in
human blood [22]. This next generation ColoAd1 vector expressing Ad3/11
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capsid proteins (Enadenotucirev) appears to be safe and effective following
intravenous (IV) injection for the treatment of distant metastases [22].

1.3 – Human adenoviruses

The Ad genome is composed of linear, double-stranded DNA of
approximately 36 kb, which can be divided into early (E) and late (L) genes
based upon their expression across the infection cycle [23, 24]. The L genes
encode structural proteins, which package the viral DNA into the Ad virion
during the final stages of replication. The E genes include E1a, E1b, E2, E3,
and E4 for regulation of viral replication. The proteins encoded by E1a are
produced immediately after infection to modulate the cell cycle, recruit cellular
proteins, and regulate the expression of cellular and viral genes [25]. The Ad
E1b gene encodes two major polypeptides, termed 55K and 19K, which are
55 kilodaltons (kDa) and 19 kDa, respectively. The expression of both
E1b55K and E1b19K is required to transform rodent cells following viral
transduction and DNA transfection [26, 27]. Both E1B55K and E1B19K
proteins protect infected cells from E1A-induced stabilization of TP53 and
apoptosis [28]. E1B55K also enhances viral E1a expression [29], and is
involved in the induction of cyclin E gene expression (which is required for
efficient Ad replication) [30-35]. The Ad E1B19K protein is a putative B-cell
lymphoma 2 protein (BCL-2) functional homolog and a strong inhibitor of
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apoptosis [36-38]. E1B19K prevents E1A-induced apoptosis by interfering
with the actions of the pro-apoptotic proteins Bak and Bax [39]. E1B19K can
also transactivate E1a during Ad infection [40]. Therefore, the actions of these
E1b-encoded proteins are thought to maximize Ad replication.

1.4 – E1b55K-deleted adenoviruses

The E1b-55K gene has been shown to bind promyelocytic leukemia
protein nuclear bodies (PML-nb) and TP53 during Ad infection [41-43]. By
interacting with PML-nbs and TP53, E1b-55K was shown to induce TP53
sumoylation as the overexpression of PML-nb and TP53 led to the
polyubiqitination and proteolytic degradation of TP53 [44]. Dr. Arnold Berk
applied this understanding of E1b-55K and TP53, to design the first E1b55Kdeleted oncolytic Ad, dl1520 in collaboration with Dr. Douglas Barker [26].

This adenovirus, dl1520, was E1b55K-deleted and was hypothesized
to be replication-deficient in primary cells expressing TP53 [45]. TP53 is the
most commonly inactivated tumor suppressor as a result of oncogenic
transformation. TP53 is mutated or deleted in approximately 50% of all human
tumors [46]. This dependence upon TP53 inactivation appeared to have led to
cancer selective cell lysis in vitro. However, Harada and Berk then tested the
dependence of dl1520 upon TP53 inactivation to induce its oncolytic effects.
Using H1299 (Tp53-deficient) lung cancer cells with inducible TP53
5

expression via a temperature-sensitive promotor (H1299-tsp53), dl1520induced H1299 CPE did not correlate with the expression of TP53 [47]. These
data suggested that the cancer selectivity of dl1520 follows a TP53independent mechanism of action.

Recent studies have indicated that E1b55K-deleted Ads can only
replicate in S-phase synchronized cancer cells [31]. E1b-55K has been
previously shown to induce cyclin E production and cyclin dependent kinase 2
(CDK2) phosphorylation [33]. Cyclin E overexpression is occurs in more than
90% of lung, liver, and gastrointestinal cancers, and in more than 80% of
glioma/blastoma, bone, and breast cancers respectively [48]. Interestingly,
E1b-deleted oncolytic Ads were only shown to induce cyclin E and p-CDK2 in
malignant cells. These data indicated that the oncogenic transformation(s)
may have led to the production of E1b55K-like factors which appear to have
recovered the attenuated CDK2/cyclin E axis activation observed by E1b55Kdeleted Ads [29]. Furthermore, these data and additional studies also suggest
that dysregulated cyclin E production may contribute to the mechanism of
E1b55K-deleted Ad cancer selectivity [30].

While the true mechanism of E1b55K-deleted oncolytic Ad cancer
selectivity remains unknown, dl1520 was safely utilized to treat several
hundred cancer patients during several phase I and II clinical trials [49].
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However, while dl1520 progressed to phase III clinical trials in combination
with cancer chemotherapy, the trial was suspended due to the limited cancer
therapeutic effects [18]. While E1b-deleted Ads, such as dl1520, were less
successful than expected clinically, these trials indicated that oncolytic viruses
were safe and an attractive drug platform for the development of cancer
therapeutics in the future.

1.5 – Oncolytic adenoviruses as lung cancer therapeutics

Ads are especially promising for the treatment of lung cancer. Ads
have respiratory tropism, allowing them to very efficiently infect and spread
throughout the lung to produce their cancer therapeutic effects [50]. Early
stage (phase I) Ad lung cancer clinical trials indicated that high doses of
replication deficient Ads were well tolerated by lung cancer patients. Some
examples

include

the

administration

of

a

TP53-expressing

Ad

by

bronchoalveolar lavage (BAL) [51] and another L523S-expressing Ad given by
intramuscular injection (IM) [52].

In a phase II clinical trial, Nemunaitis et al. administered dl1520 IV at
increasing doses to metastatic lung cancer patients [53]. Their research
revealed that dl1520 could infect and replicate within the patients’ lung cancer
tumors following IV injection with no serious side effects [53]. Furthermore,
E1b-deleted Ads interact synergistically with cancer chemotherapy, as shown
7

in primary lung cancer tissue in vitro and lung cancer xenograft models in vivo
[16, 54-56]. These studies suggest that oncolytic adenovirus therapy is safe
for the treatment of lung cancer and displays synergistic interactions in
combination with many cancer chemotherapeutics.

1.6 – Repeated cancer selection enhances oncolytic adenovirus efficacy

Most oncolytic Ads are constructed with E1b deletions and/or E1a
regulated by cancer-selective promoters. Oncolytic Ads have achieved some
success in human clinical trials however, their efficacy has been disappointing
[15, 18, 57-59]. It is possible that the rational design of the E1 gene (E1a and
E1b) modified Ads is not sufficient to induce profound cancer therapeutic
responses. Rationally designed Ads are dependent upon a nearly complete
understanding of Ad’s virus-host interactions. Therefore, it is necessary to
explore new approaches for the development of more effective oncolytic Ads.
One such approach entails the use of directed evolution. Using this approach,
Ads are exposed to DNA mutagenic agents to generate the genetic diversity
required for directed evolution and the selection of Ads with enhanced
oncolytic effects. Therefore, directed evolution may be capable of generating
Ads

with

greater

anti-cancer

activity

without

requiring

a

complete

understanding of all the virus-host interactions your Ad construct and cancer
cells of interest [30, 60-62]. In this experiment, the E1 wild-type Ad, dl309,
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was UV-irradiated prior to the selection of more effective therapeutic Ads in
cancer cells. After 72 cycles of repeated UV-irradiation and cancer selection
AdUV was isolated by plaque purification. AdUV displayed enhanced release
and spread between A549 cells. AdUV displayed greater anti-cancer efficacy
than the oncolytic Ad control, Adhz60, in all cancer cell lines tested. AdUV
also induced autophagy more effectively than either Ad5 or Adhz60 in A549
cells. AdUV also displayed increased virus release and oncolysis in Soas-2
cells (AdUV was selected in these cells). In addition, AdUV significantly
suppressed the growth of A549 xenograft tumors and prolonged the survival
of athymic nu/nu mice. These studies suggest that AdUV has potential as a
lung cancer therapeutic agent.

1.7 – The role of autophagy during Ad oncolysis

Oncolytic Ads have been shown to induce several cell death pathways
during infection such as apoptosis [63], necrosis [64] and autophagy [65, 66].
Autophagy represents an alternative form of programmed cell death, distinct
from apoptosis and necrosis [67, 68]. Autophagy leads to the sequestration of
organelles and long-lived proteins into autophagosomes, which then fuse with
the

lysosomes

forming

the

autophagolysosome

to

recycle

cellular

components [69, 70]. During autophagolysosome formation, microtubuleassociated protein 1 light chain 3 (LC3) matures from LC3-I (18 kDa) to LC3-II
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(16 kDa) [71]. Therefore, the LC3-II/LC3-I protein ratio correlates with the
abundance of autophagosomes and indicates the relative level of autophagy
induction [72, 73].

Autophagy is activated by cell stresses such as cell starvation [74],
DNA damage [75], chemotherapy treatment [76] and Ad infection [66]. Ads
have been shown to induce autophagy in glioma, ovarian and lung cancer
cells [66, 77]. Furthermore, the autophagy inhibitors 3-methyladenine (3MA)
and bafilomycin A1 (Baf-A1) were shown to protect cancer cells from Ad
oncolysis [66, 78]. Autophagy induction has also been shown to support Ad
replication [66]. These studies indicate that autophagy is crucial for Ad cancer
therapy; however, the effects of many adenovirus genes upon autophagy
remain unknown.

1.8 – E1b and its effects upon Ad oncolysis

Despite decades of pre-clinical and clinical studies, adenovirologists
have not emphasized the investigation of the mechanism of E1b-deleted Ad
oncolysis. Furthermore, the role of autophagy mediators such as c-JUN nterminal kinase (JNK) during E1b-deleted Ad oncolysis remains unclear. The
JNKs originate from 3 genes that yield 10 isoforms via alternative mRNA
splicing: JNK1α1, JNK1β1, JNK2α1, JNK2β1 and JNK3α1 which represent
the 46 kDa isoforms; and JNK1α2, JNK1β2, JNK2α2, JNK2β2 and JNK3β2
10

which represent the 54 kDa isoforms respectively [79]. The first publication, to
my knowledge, to demonstrate an interaction between E1b and JNK was
published by See and Shi in 1998. However, this report did not indicate if JNK
had an effect upon adenovirus replication or oncolysis [80]. Klein et al.
reported in 2015 that JNK expression was essential for E1b wild-type Ad
oncolysis [81]. However, their focus was upon the necessity of JNK
expression for Ad oncolysis and not the study of JNK phosphorylation by E1b
and E1a or the effect of p-JNK upon Ad replication. While Klein et al. did not
ascertain the relationship between JNK and Ad replication specifically, they
did report co-localization of hexon and p-JNK by immunofluorescence in Adinfected tumor sections, indicating that Ad replication maybe associated with
p-JNK production within tumors in vivo [81].
Other reports have suggested that autophagy induction by E1b wildtype Ads occurs independently of the molecular target of rapamycin (mTOR)
cell starvation pathway [77, 81]. Studies have demonstrated that rapamycin
treatment induced autophagy and enhanced E1b-deleted Ad replication [55,
66]. However autophagy induction by Ads appears to occur via the MKK7/pJNK/BECLIN-1 axis, perhaps due to the expression of E1b-19K [80].

I hypothesized that E1b-deleted Ads display less efficient virus
replication and oncolysis, at least in part, due to attenuated p-JNK production
in cancer cells. Previous reports and data from chapter II of this dissertation
11

show that E1b-deleted Ads induce autophagy less efficiently than E1b wildtype Ads, indicating that autophagy signaling is likely induced by E1b [66, 82];
however this phenomenon has remained uncharacterized. This dissertation
determined the effects of E1a and E1b upon JNK using Ads with selective
E1a overexpression or bearing E1b-deletions.

The JNK pathway is driven by the mitogen activated protein kinase
(MAPK) pathway, which interacts with a wide array of intracellular processes
[79]. Due to this complexity, very limited tools are available to selectively
induce p-JNK production selectively. Therefore, cancer chemotherapeutic
drugs which have been reported to induce p-JNK production were utilized:
etoposide [83], cytarabine [84], cycloheximide [85], and paclitaxel [86]. To
determine the selective effects of JNK upon Ad replication and oncolysis,
JNK1/2-siRNAs were utilized. By the completion of these studies, this
dissertation demonstrated for the first time that p-JNK production supports not
only Ad oncolysis, but also Ad replication.

1.9 – Scope of the dissertation

dl1520, the first E1b55K-deleted virus, was initially developed and
tested in the United States. Once E1b-deleted Ads were shown to have
limited cancer therapeutic efficacy in several clinical trials, their clinical
applications were aborted in the United States [15, 18, 57-59]. However, a
12

similar E1b55K-deleted Ad (H101) was approved for the treatment of head
and neck cancer patients in China [87]. Despite the success of the E1b55Kdeleted Ads, such as dl1520 and H101, the development of cancer selective
Ads with greater cancer therapeutic efficacy is necessary.

The work contained within this dissertation is focused upon enhancing
the efficacy of oncolytic Ads using multiple approaches. First, the novel Ad
mutant (AdUV) was generated using a directed evolution approach entailing
repeated UV-irradiation and cancer selection. In chapter II, AdUV displayed
enhanced autophagy induction, virus release and spread. Second, the AdUV
genome was sequenced to determine which mutations might have enhanced
its oncolytic efficiency. In chapter III, several AdUV mutations were found in
genes encoding Ad DNA packaging functions. These mutations were
hypothesized to enhance the DNA packaging efficiency of AdUV by the
inclusion of more positively-charged amino acids in these DNA binding
proteins. These mutations may have facilitated greater binding to the
negatively-charged DNA sugar-phosphate backbone. AdUV was also shown
to replicate within and suppress the growth of A549 tumor xenografts while
remaining non-lethal to AdUV-treated mice.

While Ads have been extensively researched, the mechanism of Adinduced oncolysis and which cell death pathways should be targeted to
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enhance Ad therapy remain unknown. Therefore the third approach in this
dissertation to enhance Ad therapy, I expanded upon the literature’s
description of Ad induced JNK phosphorylation and determined if p-JNK
production enhanced Ad oncolysis [80, 88]. In chapter IV, E1b-deleted Ads
displayed less p-JNK, which appeared to be induced by E1b-19K. These data
indicated that E1a led to increased p-JNK production. The cancer
chemotherapeutic, etoposide, was shown to induce p-JNK and enhance Ad
oncolysis. JNK1/2-targeting siRNA confirmed that JNK was essential for Ad
replication and A549 cell oncolysis.

Ultimately, by uncovering Ad genes associated with increased Ad
spread and understanding how Ads interact with the JNK pathway may help
to overcome the limitations facing Ad oncolytic virotherapy and lead to
development of more effective oncolytic Ads.

14

CHAPTER II
DEVELOPMENT OF AN ONCOLYTIC ADENOVIRUS WITH ENHANCED
SPREAD ABILITY THROUGH REPEATED UV IRRADIATION AND CANCER
SELECTION
2.1 – Introduction

Human Ads have been modified to selectively replicate and lyse cancer
cells [89]. Ads exhibit their favorable safety profile because they only cause
negligible flu-like symptoms and cannot integrate their genomes into the host
cell chromosomes [23]. The therapeutic effects of oncolytic Ads are initiated
from a small number of infected cancer cells from which the progeny viruses
are released to infect adjacent cancer cells further within tumors [12, 14].
However, preclinical and clinical studies have suggested that Ad spread is
restricted in large tumors, limiting their therapeutic efficacy.
The development of oncolytic Ads has focused primarily upon the
genetic manipulation of E1a and E1b. At least two approaches have been
applied for the development of oncolytic Ads to date. One approach is to
delete or attenuate E1b, the expression of which is not essential for virus
replication in cancer cells. For example, dl1520 (ONYX-015) is a geneattenuated oncolytic virus with an 827-bp deletion and a nonsense point
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mutation in the E1b region which generates a premature stop codon,
preventing the complete translation of the E1B55K protein; therefore, dl1520
is functionally E1b55K-deleted [15, 26, 90]. Several hundred cancer patients
were treated with dl1520 via various routes of administration in phase I and II
clinical trials [49]. However, during a phase III clinical trial when dl1520 was
combined with cancer chemotherapy to treat head and neck squamous cell
carcinoma patients, the trial was suspended due to the limited therapeutic
effects [18].
Another approach to develop cancer selective Ads is to regulate the
transcription of essential viral genes, such as E1a, with tumor-specific
promoters to restrict the expression of viral regulatory genes and oncolytic
Ads within tumors rather than normal tissue [14, 91]. Ad-cycE was recently
developed and expresses E1a under the control of the cyclinE promoter to
produce cancer selective oncolytic effects [34, 35, 55]. Furthermore, the
replication of Ad-cycE is further stimulated by Ad infection, augmenting the
oncolytic efficacy of Ad-cycE [30, 31]. Ad-cycE can selectively replicate in a
diverse range of cancer cells and was shown to significantly repress tumor
growth, prolonging the survival of xenograft tumor bearing mice [34, 55].
Other examples of oncolytic Ads with cancer-selective promoters include,
OBP-301 (Telomelysin®) which expresses E1a under the control of the
human telomerase reverse transcriptase (hTERT) promoter [92], and CV706
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which expresses E1a under the control of the prostate-specific antigen (PSA)
promoter [93]. Both Telomelysin® and CV706 have progressed to human
clinical trials but have shown limited cancer therapeutic efficacy.
Although Ads with E1b deletions and/or E1a regulated by cancerselective promoters have achieved some success in human clinical trials, the
efficacy of oncolytic Ad virotherapy overall has been disappointing [15, 18, 5759]. Oncolytic Ads were previously shown efficiently inhibit the growth of only
small tumors in vivo following intratumoral (IT) injection [59]. This
phenomenon was also observed during clinical studies, as the direct injection
of dl1520 did not inhibit the growth of larger tumors clinically [15, 58].
Restricted virus spread in larger tumors likely presents a significant barrier to
the efficacy of Ad virotherapy [94]. It appears that extensive genetic
manipulation of E1a and/or E1b is not sufficient to overcome these Ad
therapeutic barriers. Therefore, it is necessary to explore new approaches to
develop more effective oncolytic Ads.
In this study, the E1 wild-type dl309 (Ad5) was UV irradiated, followed
by repeated selection in Soas-2 cancer cells. These treatments were repeated
for total 72 cycles to select for Ads which can efficiently release from and
spread between cancer cells. This approach targeted the entire genome
rather than focusing upon the E1 region exclusively. Using this approach, the
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oncolytic virus AdUV was isolated. AdUV displayed the properties of
enhanced oncolytic replication and spread in vitro.
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2.2 – Materials and Methods
Cell Lines and Culture Conditions
HEK293 (ATCC no. CRL-1573) human embryonic kidney cells, MRC5
(ATTCC no. CCL-171) human non-cancerous fibroblasts, HBEC (ATTCC no.
CRL-4051) human non-cancerous epithelial cells, A549 (ATCC no. CCL-185)
human lung carcinoma cells, H1299 (ATCC no. CRL-5803) metastatic human
lung carcinoma cells isolated from lymph nodes, H441 (ATCC no. HTB-174)
human lung papillary adenocarcinoma cells, MCF-7 (ATCC no. HTB-22)
human breast adenocarcinoma cells, and Saos-2 human bone osteosarcoma
cells (ATTCC no. HTB-85) were obtained from the American Type Culture
Collection (Rockville, MD, USA). A549, MCF-7, MRC5, and HEK293 cells
were maintained in DMEM. H1299 and H441 cells were cultured in RPMI
1640 medium. Saos-2 cells were maintained in McCoy’s 5A media. HBEC
cells were maintained in keratinocyte serum-free medium containing bovine
pituitary extract and recombinant epidermal growth factor (Invitrogen,
Waltham, MA, USA). All cell culture media were supplemented with 10% fetal
bovine serum, 5%

L-glutamine,

and 5% penicillin/streptomycin (100 U/mL)

unless indicated otherwise. All cells were cultured and maintained in humidified
5% CO2 incubators at 37 °C. All other cell culture reagents were obtained from
VWR (VWR, Radnor, PA, USA) unless indicated otherwise.
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Adenoviral Vectors
Ad5, dl309, is E1 wild-type virus [95] and was used as a non-selective
Ad control. Adhz60 with a deletion of the entire E1b gene was used as a
cancer selective Ad control [96]. AdGFP is an Ad vector with the entire E1
gene (E1a and E1b) deleted, expressing GFP driven by the cytomegalovirus
(CMV) promoter. AdGFP, as a negative control, does not replicate nor induce
CPE. All Ads used in this study are based on the Ad5 backbone sequence.
To select for Ads with increased spread, cell culture media containing
Ad5 dl309 was UV-irradiated for 5 min using a UV-light germicidal lamp,
inactivating approximately 90% of virus particles. The UV-light source was a
germicidal lamp, USEG30T3 (Sylvania, Danvers, MA, USA), fitted with a 30
watt G30T8 UV-light bulb (Philips, Amsterdam, The Netherlands), which
produces UV type-C irradiation. UV irradiation was measured with a 25X UVX
radiometer (Fisher Scientific, Pittsburgh, PA, USA). Using these conditions,
213 μW/cm2 UV type-C was produced, generating a total UV dose of 639 J/m2
after 5 min exposure. Irradiated viruses were then used to infect Saos-2
cancer cells, in which Ads cannot efficiently replicate [31]. Four h after
infection, extracellular virus particles were removed by washing the cells with
fresh media. The cell culture media were collected at the first sign of CPE,
generally at 24 h after infection, to harvest viruses that might replicate and
release from the infected cancer cells more efficenctly. The harvested viruses
were then amplified in 293 cells before being used for another cycle of UVirradiation. These treatments were repeated for total 72 cycles and AdUV, that
formed a large plaque on Saos-2 cells, was isolated (Figure 1).
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Reprinted with permission: Wechman et al., Viruses, 2016

Figure 1. The repeated UV irradiation and cancer selection of
AdUV. Ad5 dl309 was initially amplified in HEK293 cells prior to UVirradiation. Irradiated viruses (dl309IR) were then selected in Saos-2
cancer cells. Viruses were then harvested from Saos-2 cells and
amplified in HEK293 cells before subsequent cycles of UV irradiation.
After 72 cycles of UV irradiation and cancer selection, AdUV was
isolated by plaque purification from a large plaque formed upon Saos2 cells.
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Virus Titration and Release
Virus titer was determined using the TCID50 method as described
previously [33]. HEK293 cells were seeded overnight onto 96-well plates at a
density of 1 × 103 cells per well and infected with virus samples serially diluted
10 fold. The presence or absence of CPE in HEK293 cells was then recorded
after a minimum of 7 days to calculate the virus titer.
To determine the release kinetics of AdUV, A549 cells were seeded
onto 12-well plates at a density of 1 × 105 cells per well. A549 cells were then
infected with Ad5, Adhz60 or AdUV at an MOI of 1. Samples were collected at
6, 24, 36, 48, and 72 h after infection. The cells and cell culture media were
separated by centrifugation at 2000 RPM (350 RCF) at 4 °C for 5 min using a
micromax RF refrigerated microcentrifuge equipped with an IEC 851 rotor
(Thermo Fisher Scientific, Waltham, MA, USA). Cell pellets were then
resuspended in 1 mL of sterile phosphate buffered saline (PBS) and
subjected to 3 freeze-thaw cycles to release viruses contained within cells
prior to titration. Cell free media samples were titered to detect viruses
released from cells. For studies focusing upon virus titer in the media alone,
cells were infected at 1 MOI and media samples (20 μL) were collected daily
for 5 days.
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Western Blot Analysis
A549 cells were seeded onto 60 mm dishes at a density of 6 × 10 5 cells
per dish incubated overnight. Cells were collected and centrifuged at 1500
RPM (453 RCF) at 4 °C for 5 min using an Eppendorf 15 amp 5810 R
refrigerated centrifuge equipped with a A-4-62 rotor (Eppendorf, Hamburg,
Germany). The cell pellets were then washed with PBS prior to lysis with radio
immunoprecipitation assay (RIPA) buffer containing 50 mM Tris-HCl, 150 mM
NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% sodium docecyl
sulfate (SDS) with a protease inhibitor (PI) cocktail containing 4-(2aminoethyl)-benzenesulfonyl

fluoride

(AEBSF),

pepstatin

A,

trans-

epoxysuccinyl-L-leucylamido-(4-guanidino)butane (E-64), bestatin, leupeptin,
and aprotinin (10 mL / 1 × 106 cells; Sigma, St. Louis, MO, USA). The cell
lysates were then incubated on ice in PI containing RIPA buffer for 30 min and
homogenized every 10 min using a vortex-genie 2 (Scientific Industries,
Bohemia, NY, USA). These lysates were then centrifuged at 14,500 RPM
(196,000 RCF) at 4 °C for 10 min using a micromax RF microcentrifuge
equipped with an IEC 851 rotor to pellet cell debris formed during lysate
preparation (Thermo Fisher Scientific, Waltham, MA, USA). The pellet was
discarded and the supernatant was stored at −80 °C for further
experimentation. Protein concentrations were determined using the Pierce
BCA protein assay kit according to the manufacturer’s instructions (Thermo
Fisher Scientific, Waltham, MA, USA). Equal amounts of cellular protein were
resolved by electrophoresis through 8% (E1A, hexon, penton, protein V,
protein VI, protein VII) or 12% (LC3-I and LC3-II) SDS-polyacrylamide gels
prior to transfer to methanol activated PVDF membranes (GE healthcare,
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Little Chalfont, UK) using a semi-dry transfer apparatus (BIO-RAD, Hercules,
CA, USA). Membranes were then blocked using 5% nonfat milk prepared in
TBST for 1 h at room temperature. To detect protein expression, membranes
were incubated with the following primary antibodies: rabbit-anti-adenovirus
type 5 (1:10,000; Abcam, Cambridge, UK), rabbit-anti-human-LC3 (1:3000;
Novus Biologicals, Littleton, CO, USA), rabbit-anti-human-actin (1:2000;
Sigma, St. Louis, MO, USA) or mouse-anti-adenovirus-E1A antibody (1:1000;
BD Pharmagen, San Jose, CA, USA) at 4 °C overnight on a lab-line thermal
rocker (Thermo Fisher Scientific, Waltham, MA, USA). Primary antibody
binding was detected by the incubation with the horseradish peroxidase
(HRP) linked anti-mouse or anti-rabbit immunoglobulin (Ig) diluted 1:5000 for
1 h at room temperature (Amersham, Piscataway, NJ, USA). All antibodies
were diluted in TBST. Enhanced chemiluminescence (ECL) reagents were
used to detect HRP-linked secondary antibody binding according to the
manufacturer’s instructions (Amersham, Piscataway, NJ, USA).
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Plaque Formation Assay
A549 cells were seeded onto 6-well plates at a density of 3 × 105 cells
per well. Cells were then infected with Ad5, Adhz60 and AdUV at an MOI of
0.01. The cell culture media were removed after 6 h and replaced with 5 mL of
sterile DMEM, 1% agarose heated gell per well. This gell overlay was then
allowed to become solid at RT. Images were taken 6 days post-infection with
an EVOS FL microscope (Life Technologies, Carlsbad, CA, USA) at 4× total
magnification. The pixels contained within 10 representative plaques per Ad5,
Adhz60, and AdUV treatment groups were quantified with the area density
tool using Gel-pro analyzer 4.0 software according to the manufacturer’s
tutorial (Media Cybernetics, Rockville, MD, USA). The total number of pixels
for each plaque was converted to millimeters squared (mm2) by dividing the
number of pixels per plaque by the number of pixels per 1 mm2 (261,100
pixels) or squared pixel length of the 1000 micrometer (μm) scale bar (510
pixels).
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Quantification of Band Intensity
Band intensities were quantified by Gel-pro analyzer 4.0 software in
accordance with the manufacturer’s tutorial (Media Cybernetics, Rockville,
MD, USA). Densitometric values were expressed as the absolute integrated
optical density (IOD) of each band normalized to actin expression as
described previously [55]. Mock treated cells were represented as 1 fold LC3II/LC3-I production for each experiment.
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Cytotoxicity Assay
Cells were seeded overnight at a density of 2 × 10 4 (H1299), 2.5 × 104
(MRC5), 3 × 104 (HBEC), 3 × 104 (A549), 4 × 104 (MCF-7), or 6 × 104 (H441)
cells per well in 24-well plates. Cytotoxicity was assessed by crystal violet
staining [97]. Suspended cells were removed by aspiration, the remaining
adherent cells were then fixed with 3.7% formaldehyde for 20 min at room
temperature. The excess formaldehyde was washed off with PBS; the cells
were then stained using 1% crystal violet at room temperature for 30 min.
Excess crystal violet was washed away with water. Plates were then scanned
using an HP Scanjet 4070 scanner (HP, Palo Alto, CA, USA). The remaining
crystal violet was then solubilized with a 2% SDS solution and the sample
absorbances (OD) were measured at 590 nm using a Synergy HT Multi-Mode
Microplate Reader (Bio-Tek, Winooski, VT, USA). The OD values of each
treatment were then normalized to mock-treated cells converting each sample
OD into the percent (%) of cell viability according to the formula, cell viability
% = (OD of treated cells / OD of mock-treated cells) × 100%. A549 cells
displaying CPE were photographed at 200× magnification using an Olympus
BX53 microscope (Olympus, Center Valley, PA, USA).
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Statistical Analysis
All experiments were repeated at least 3 times. Quantification of results
was reported as means of 3 independent experiments plus or minus (±) the
standard deviation. The Pearson correlation coefficient (r) was used to
evaluate the accuracy of equations used to calculate sample protein
concentrations with the Pierce BCA protein assay kit. Statistical significance
was assessed using analysis of variance analysis (ANOVA) for parametric
data

and

the

Kruskal-Wallis

test

for non-parametric

data.

Multiple

comparisons of ANOVA tests were corrected using Bonferroni’s method.
Multiple comparisons of Kruskal-Wallis one-way analyses were corrected by
Dunnett’s test. All statistical tests were conducted using GraphPad PRISM 6
software (Microsoft, Redmond, WA, USA).
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2.3 - Results
AdUV Displays More Efficient Release and Cancer Cell Lysis
AdUV was generated as illustrated in Figure 1. Briefly, AdUV was
isolated from a pool of dl309 (Ad5) viral particles that were repeatedly treated
with UV irradiation and selected in cancer cells for 72 cycles. To evaluate the
potency of AdUV in lung cancer cells, A549 cells were infected with the
increasing MOIs of AdGFP, Ad5, Adhz60, or AdUV for 5 days (Figure 2A).
The differences among treatment groups were greatest at an MOI of 3; these
cancer cell viabilities were 20, 60, and 90% after treatment with AdUV, Ad5,
or Adhz60, respectively (Figure 2B). Morphologically, AdUV induced greater
cell rounding, consistent with CPE relative to A549 cells treated with Adhz60,
Ad5 (Figure 2C). These data indicated that AdUV efficiently destroyed A549
human lung cancer cells.
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Reprinted with permission: Wechman et al., Viruses, 2016

Figure 2. AdUV is released from and lyses A549 cells more
efficiently than Adhz60. (A) A549 cells stained with crystal violet
after five days’ treatment with the indicated Ads and MOIs; (B)
Quantification of A549 cells stained with crystal violet expressed at
the percent (%) viability; (C) CPE in A549 cells treated at an MOI of 1
for the indicated Ads were photographed at 200× total magnification
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five days post-infection; (D) A549 cells were infected with at an MOI
of 1 with Adhz60 and AdUV and media samples were collected daily
until day 5. Ad titer was determined via the TCID50 method using
HEK293 cells. Day 0 represents samples collected at 6 h postinfection; (E) Crystal violet staining of non-cancerous lung fibroblasts
(MRC5) and epithelial (HBEC) cell lines treated at an MOI of 10 for 3
days. Quantified data are shown ± the standard deviation (SD) of 3
independent replicates. Statistical significance was assessed relative
to the oncolytic Ad control Adhz60 via two-way ANOVA relative to
Adhz60 treated cells with multiple comparisons corrected for by
Bonferroni’s method. ‡ indicates p-value < 0.001.

The enhanced lysis of A549 cells by AdUV prompted additional studies
to determine if AdUV was released from cells more efficiently. To determine
the release kinetics of AdUV, A549 cells were infected with AdUV and Adhz60
and media samples were then collected at 0, 1, 2, 3, 4, and 5 days postinfection (Figure 2D). Viral titers were then determined to quantify the number
of virus particles released into culture media at each time-point. The titers for
both viruses within the cell culture media increased with time; however, AdUV
media titers were greater at each time-point than Adhz60. At day 2, AdUV titer
(3 × 107) was 40.5 fold greater than Adhz60 (7.4 × 105) in the cell culture
media (Figure 2D). To evaluate the cancer selectivity of AdUV, MRC5 and
HBEC non-cancerous cells were infected with negative control AdGFP, the
cancer non-selective Ad5, and the cancer-selective Adhz60 and AdUV at an
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MOI of 10. These data indicated that AdUV lysed MRC5 and HBEC noncancerous cells less efficiently than the cancer non-selective Ad5 however,
AdUV lysed more non-cancerous cells than the cancer selective Adhz60;
indicating that AdUV is at least partially cancer selective (Figure 2E).
To verify the enhanced release and spread of AdUV, plaque assays
were conducted. The plaque assay is based on the ability of a single
infectious viral unit (IFU) to replicate in cells and release a large number of
progeny that can infect neighboring cancer cells, finally forming a
macroscopic area of cytopathology, or plaque, on a monolayer of cultured
cells. Viruses that can efficiently replicate and release a greater number of
viral particles will presumably form larger plaques. In this study, nearly
confluent (70%) A549 cells were infected with Ad5, Adhz60, or AdUV. Initial
plaque formation was observed 4 to 5 days post-infection. At day 6 postinfection, at least 10 plaques formed by each virus were studied. The average
size of plaques formed by Ad5, Adhz60, and AdUV were 0.883, 0.534, and
1.680 mm2, respectively; plaques formed by AdUV were 314% larger than
those plaques formed by Adhz60 and 190% larger than those of Ad5 (Figure
3A,B; 2 representative plaques per treatment are shown). These differences
were shown to be statistically significant. These studies taken together
indicate that AdUV is released and spreads more effectively than Ad5 and
Adhz60 in A549 lung cancer cells.
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Reprinted with permission: Wechman et al., Viruses, 2016

Figure 3. AdUV spread in A549 cells. (A) Two representative
plaques of Ad5, Adhz60 and AdUV treated A549 cells are shown at
4× magnifications; (B) Using the 1000 µM scale (or 1 mM), the
number of pixels contained within each plaque was calculated by
dividing by the number of pixels contained within each plaque by the
number of pixels per 1 mm2 to determine the size of each plaque in
square millimeters (mm2). These data were then plotted as the
average ± the SD of these 10 quantified plaques. Statistical
significance was assessed using the Kruskal-Wallis test. Adjusted pvalues were reported for multiple comparisons via Tukey’s test. n.s.
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indicates p-value < 0.05, * indicates p-value < 0.05, ‡ indicates p-value
< 0.001.
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Improved AdUV Replication in Cancer Cells
To investigate whether the large plaque formation phenotype of AdUV
was related to increased virus replication, viral early (regulative) and late
(structural) protein production was studied in A549 cells by Western blot
analysis. The E1b-deleted Adhz60 produced much less E1A than the E1b
wild-type Ad5 in A549 cells at 48 h (Figure 4A). This result was expected
because E1b expression has been supports E1A production during Ad
infection [29]. At 48 h, AdUV induced peak E1A production. The level of AdUV
E1A production was even greater than the cancer non-selective wild-type Ad
Ad5 (Figure 4A). At 72 h, the production of E1A by AdUV decreased, while
Adhz60-mediated E1A production increased (Figure 4A). Following the rapid
expression of E1A proteins by AdUV, late protein production was also shown
to increase to levels much greater than Adhz60 and comparable to Ad5 at 72
h (Figure 4A).
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Reprinted with permission: Wechman et al., Viruses, 2016

Figure 4. AdUV virus replication in A549 lung cancer cells. (A)
The expression of the Ad E1A and late genes were observed in A549
cells treated with the indicated Ads at an MOI of 1 following 6 h, 24 h,
48 h, and 72 h infection; (B) Virus titer outside of A549 cells treated
with the indicated Ads at an MOI of 1. Samples were collected at the
indicated time-points. At 36 h, the number of virions of released in the
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cell culture media was 7 fold for Ad5 and 24 fold for AdUV when
normalized to Adhz60 titer; (C) Virus titer inside of infected A549 cells
treated with the indicated Ads at an MOI of 1. Samples were collected
at the indicated time-points. At 36 h, the titers of both AdUV and Ad5
inside of cells were 9 fold greater than Adhz60. Data is presented as the
average titer ± SD of 3 independent replicates. Significance was
determined via the Kruskal-Wallis test. Adjusted p-values were reported
for multiple comparisons via Dunnett’s test. h indicates hours, * indicates
p-value < 0.05.
To study the oncolytic replication and release of AdUV further, A549
cells were infected with AdUV, Ad5, or Adhz60 at an MOI of 1. In this
experiment, the cell culture media and total cells were collected at 6, 24, 36,
48, and 72 h post-infection. The cells and culture media were separated via
centrifugation to determine the titers of Ads within cells and of viruses
released into the culture media. The titers of AdUV released into the cell
culture media were 5 × 106 at 36 h which was greater than both Ad5 (1.5 ×
106) and Adhz60 (1.5 × 105; Figure 4B, left). When these data were
normalized to Adhz60 titer, AdUV was 24 fold while Ad5 titer was 7 fold
greater than Adhz60 (Figure 4B, right). The viral titers of AdUV and Ad5 within
cancer cells were similar; the titers of both AdUV and Ad5 were consistently 5
to 10 fold greater than Adhz60 from 24 to 72 h within A549 cells and were 9
fold greater than Adhz60 at 36 h (Figure 4C). These data indicate that AdUV
replicates and is released more rapidly from A549 cells than Adhz60. It is
likely that the rapid release of AdUV supports its ability to form large plaques
in A549 cells.
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AdUV is a Greater Autophagy Inducer
Ads have been shown to induce autophagy to enhance virus replication
[66]. Autophagy leads to the sequestration of organelles and long lived
proteins into autophagosomes, which then fuse with lysosomes, forming the
autophagolysosome

to

recycle

cellular

components

[69].

During

autophagolysosome formation, microtubule-associated protein 1 light chain 3
(LC3) matures from LC3-I (18 kDa) to LC3-II (16 kDa) [71]. Therefore, the
LC3-II/LC3-I protein ratio can be used to estimate the abundance of
autophagosomes and indicate the relative levels of cellular autophagy
induction [72, 73].
To study autophagy induction by AdUV, A549 cells were treated with
AdGFP, Ad5, Adhz60, or AdUV at an MOI of 1. Large vesicles were observed
in the cytoplasm of A549 cells treated with Ad5 and AdUV, but not with
AdGFP or Adhz60 (Figure 5A, arrowheads). The presence of such vesicles is
a morphological marker of autophagy induction. Autophagy induction was
evaluated further via the observation of LC3 production via Western blot
analysis. Relative to mock, the LC3-II/LC3-I expression ratio increased to
30.9, 12.2, and 7.8 fold for AdUV, Ad5, and Adhz60, respectively (Figure 5B).
AdUV treatment displayed the greatest LC3-II/LC3-I fold expression ratio.
According to these data, AdUV induced autophagy much more effectively
than either Ad5 or Adhz60 in A549 cells.
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Reprinted with permission: Wechman et al., Viruses, 2016

Figure 5. AdUV induces greater autophagy in A549 cells. (A)
Pictures of A549 cells (400× total magnifications) treated with the
indicated Ads at an MOI of 1 for 3 days. Boxes indicate the magnified
(~9.3× total magnifications) to emphasize the presence or absence of
vesicle formation in the cytoplasm. Arrows were used to indicate
these vesicles. Scale bar (top right) is indicative of 600 µm; (B) A549
cells were treated with the indicated Ads at an MOI of 1 for 5 days
and observed for LC3 expression by Western blot analysis.
Densitometric analysis of LC3-II to LC3-I and actin were performed
using Gel-pro analyzer 4.0 software. LC3 expression was normalized
to actin expression.
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AdUV Kills a Variety of Cancer Cell Lines
To study the oncolytic effects of AdUV upon other cancer cell lines,
A549, H1299, and H441 lung cancer cells, as well as MCF-7 breast cancer
cells were treated with increasing MOIs of AdGFP, Ad5, Adhz60, or AdUV for
5 days. Cell viability was assessed via crystal violet staining and normalized
to mock-treated cancer cells (Figure 6A). The negative control AdGFP did not
alter treated cell viability while treatment with the positive control Ad5 was
shown to efficiently lyse all cancer cell lines tested. AdUV lysed A549 cells
with significantly greater efficiently than both Ad5 (p-value = 0.005) and
Adhz60 (p-value = 0.0002) at 0.3 MOI (Figure 6A). AdUV killed H1299 lung
cancer cells 64%, comparing with 8% of Adhz60 and 18% of Ad5 treatment at
the same condition (0.3 MOI). Compared with the E1b-deleted Ad Adhz60,
AdUV also efficiently destroyed H441 lung cancer cells and MCF-7 breast
cancer cells (Figure 6A). The EC50s of AdUV were 0.99, 1.12, 1.12, and 1.76
for A549, H1299, H441 and MCF-7, respectively (Figure 6B). Adjusted pvalues for multiple comparisons indicated that statistically significant
differences were observed between the AdUV and Adhz60 treatment groups
in all cancer cell lines treated at an MOI of 1 except MCF-7 (Figure 6C).
Therefore, AdUV induced the oncolysis of multiple cancer cell lines much
more effectively than Adhz60.
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Reprinted with permission: Wechman et al., Viruses, 2016

Figure 6. AdUV kills multiple cancer cell lines more effectively
than Adhz60 in vitro. (A) A549, H1299, H441 lung cancer cells and
MCF-7 breast cancer cells were treated with the indicated MOIs and
Ads for 5 days prior to staining with crystal violet. The amount of
crystal violet staining was quantified and expressed as the percent
(%) viability of treated cells relative to non-treated cells ± the standard
deviation of 3 independent experiments; (B) EC50 values were
determined using GraphPad PRISM software; (C) Two-way ANOVA
with multiple comparisons were conducted between all Ad treatments
across all cancer cell lines at an MOI of 1. Adjusted p-values were
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reported for multiple comparisons via Bonferroni’s method. d.n.e.
indicates that the EC50 does not exist, * Indicates a p-value < 0.05,
indicates a p-value < 0.01, ‡ indicates a p-value < 0.001.
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2.4 - Discussion
All clinical studies have shown that the efficacy of Ad virotherapy,
specifically dl1520/ONYX-015 and H101, has remained low [15, 17, 18, 57,
58, 98-100]. Ad spread within solid tumors was limited to cancer cells in the
immediate vicinity of the injection site in clusters of 5-20 cells during clinical
studies [101-103]. In the Dr. McMasters lab, intratumorally (IT) injected Ads
localized within capsule-like structures in syngenic xenograft bearing mice
[35]; the formation of these capsules likely prevented Ad spread throughout
the entire tumor mass, limiting its therapeutic outcomes. These data indicated
that Ad spread is restricted in tumors and may have antagonized the efficacy
of Ad virotherapy [94].
The development of Ad vectors with increased spread would likely lead
to enhanced cancer therapeutic efficacy for the treatment of solid tumors.
Most Ads used clinically are E1 gene modified. E1-modified Ads have been
the focus of clinical studies primarily because the functions of E1 are well
characterized relative to many of the other Ad genes, whose effects upon Ad
replication in cancer cells are not understood. Therefore, it is difficult to predict
the biological consequences resulting from the genetic manipulation of nonE1 Ad genes. An alternative strategy to develop oncolytic Ads is to use
random mutagenesis to introduce changes to the viral genome and then
select for mutant Ads with the desired properties. Such directed evolution has
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been shown to enhance the oncolytic efficacy of other viruses such as the
recombinant Newcastle disease virus MTH87 [62] and Ad5 [60, 61]. In this
study, dl309 (Ad5) was treated with UV irradiation and then selected from the
pool of the UV-irradiated viruses for efficient replication in and release from
cancer cells. This approach differs from previous reports as Ad particles were
treated with DNA-damaging agent a total of 72 times throughout the cancer
selection process. After 72 cycles of UV irradiation and cancer selection,
AdUV was isolated. AdUV formed larger plaques than both Adhz60 and Ad5
in cancer cells, indicating greater viral spread. Furthermore, AdUV displayed
greater anti-cancer potency and efficacy in all cancer cell lines tested. These
studies demonstrated the efficacy of AdUV in vitro.
Previously, Ad infection was shown to increase the conversion of LC3-I
to LC3-II, inducing autophagy, which positively correlates with enhanced viral
replication and oncolytic cell death. This suggests that autophagy may
generate macromolecules to support Ad assembly and replication [66].
Results presented in chapter II have shown that AdUV induced LC3-II
conversion more effectively than either Ad5 or Adhz60 in cancer cells.
Furthermore, the autophagy inducer verapamil, an L-type Ca2+ channel
antagonist, has been shown to increase Ad spread between cancer cells in
vitro [104], indicating that increased autophagy induction by AdUV may have
led to its large plaque formation phenotype in addition the increased release
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of AdUV. The autophagy inhibitor 3MA, a phosphatidylinositol 3-kinase (PI3K) and autophagosome formation inhibitor, was shown to inhibit the
replication and oncolysis of Ad infected cancer cells validating these findings
[66]. Ad-mediated cancer cell lysis may also be related to the induction of
apoptotic [36] and necrotic [64] cancer cell death pathways. Conflicting
reports also indicate that wild-type serotype 5 Ads (Ad5) kill cancer cells
independently of caspase activation and TP53 expression [64, 105]. While the
molecular mechanism of enhanced AdUV cytolysis remains unclear, enhanced
autophagy induction appears to play an important role.
One limitation of this approach is that multiple mutations may be
introduced into the viral genome. Ascertaining the effects of an individual
mutation upon virotherapy from mutagenesis and cancer selection is complex.
To determine which mutation or combination of mutations has the greatest
effect upon this enhanced oncolysis phenotype, additional in vitro and in vivo
studies are necessary to characterize these mutations and is the subject of
future investigation.
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Reprinted with permission: Wechman et al., Viruses, 2016

Figure 7. AdUV DNA mutation map. 30 mutations were detected in
the AdUV genome in total, relative to the Ad serotype 5 (Ad5)
reference sequences. No mutations were present in the early genes.
The majority of these mutations were contained in Ad late genes.
Mutations are indicated by exclamation points. Data was collected via
ION torrent DNA sequencing and viewed with open source IGV
software.
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In this study, these data indicated that AdUV, developed through repeated
mutagenesis and selection in cancer cells, has displayed many favorable
characteristics and has substantial potential as a cancer therapeutic platform.
The enhanced cancer cell lysis by AdUV appears to be related to the
increased viral replication and release from infected cancer cells, as well as
increased autophagy induction. This study has also indicated the utility of this
approach for the development of other oncolytic viruses with designated
therapeutic properties.
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CHAPTER III
ADENOVIRUS WITH DNA PACKAGING GENE MUTATIONS INCREASED
VIRUS RELEASE
3.1 – Introduction

In the preceding chapter, AdUV was isolated from a pool of the Ad
serotype 5 dl309 (Ad5) viral particles which were repeatedly treated with UV
type-C irradiation and selected for rapid cancer cell lysis. AdUV was shown to
lyse cancer cells very effectively and form large viral plaques on cancer cell
monolayers [82]. In this chapter, we extended the description of AdUV in
Chapter II to identify AdUV genome mutations. No mutations were observed
in the early genes (E1, E4) in AdUV, but several mutations were found within
the late genes encoding Ad structural proteins involved in viral DNA
packaging. AdUV was shown to effectively lyse cancer cells while safely and
efficiently suppressing tumor growth using an athymic nude mouse (NCrnu/nu) xenograft model.
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3.2 – Materials and Methods
Cell Lines and Culture Conditions
HEK293 (ATCC no. CRL-1573) human embryonic kidney, MRC5
(ATCC no. CCL-171) human non-cancerous lung fibroblast, HBEC (ATCC no.
CRL-4051) human non-cancerous human bronchial epithelial cells, A549
(ATCC no. CCL-185) human lung carcinoma and Saos-2 (ATCC no. HTB-85)
human osteosarcoma cells were all purchased from the ATCC (Rockville, MD,
USA). A549, MRC5 and HEK293 cells were maintained in Dulbecco's
Modified Eagle's Medium (DMEM). Saos-2 cells were maintained in McCoy’s
5A media. DMEM and McCoy’s 5A media were supplemented with 10% fetal
bovine serum, L-glutamine, and penicillin/streptomycin (100 U/mL). HBEC
cells were cultured in airway epithelial cell basal medium (ATCC PCS-300030) supplemented with bronchial epithelial cell growth kit (ATCC PCS-300040). All cells were cultured and maintained in humidified 5% CO2 incubators
at 37 °C.
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Adenoviral Vectors
Ad5 dl309 is E1 wild-type [95] and was used as a non-selective Ad
control. This virus also contains deletions in E3, preventing the expression of
E3B10.4K, 14.6K, and 14.7K, but not the E3A glycoprotein (gp) 19K gene
[95]. Adhz60 is an E1b-deleted vector similar to dl1520 and H101 and was
used as a cancer selective control in these studies [96]. AdGFP is E1 (E1a
and E1b) deleted, with green fluorescent protein (GFP) expression driven by
the CMV promoter [55]. AdGFP, as a negative control, does not replicate nor
induce CPE [34, 35]. All Ads used in this study express E1 and E4 unless
otherwise specified, and are based upon Ad5 backbone sequences
(GENEID# AC_000008.1).
To select Ads with increased spread, Ad5 dl309 was treated with UV
irradiation for 5 min, inactivating approximately 90% of virus particles. The
UV-light source was a germicidal lamp, USEG30T3 (Sylvania, Danvers, MA,
USA), fitted with a 30 watt G30T8 UV-light bulb (Philips, Amsterdam, The
Netherlands), which produces UV type-C irradiation. UV irradiation was
measured with a model 25X UVX radiometer (Fisher Scientific, Pittsburgh,
PA, USA). Using these conditions, 213 μW/cm 2 UV type-C was produced,
generating a total UV dose of 639 J/m 2 after 5 min exposure. Irradiated
viruses were then used to infect Saos-2 cancer cells, in which Ads cannot
replicate as well as in HEK293 and A549 cells [31]. Four h after infection,
virus particles in the medium were removed by washing the cells with fresh
media. Medium from infected monolayer cultures was collected at the first
sign of CPE, generally at 24 h after infection, to harvest viruses that might
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replicate more efficiently in and release from the infected cancer cells. The
harvested viruses were then amplified in HEK293 cells before subsequent
cycles of UV-light treatment. These treatments were repeated for 72 cycles.
AdUV was then isolated from a mixture of viruses by plaque purification and
selection for those Ads forming large plaques on Saos-2 cells as previously
described [82].
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Virus Titration and Release
Virus titer was determined using the median tissue culture infective
dose (TCID50) method [33, 59, 106]. HEK293 cells were seeded overnight
onto 96-well plates at a density of 1 × 103 cells per well and infected with virus
samples serially diluted 10 fold. The presence or absence of CPE in HEK293
cells was recorded, after a minimum of 7 days, to calculate Ad titer.
To determine the release kinetics of AdUV, A549 and Saos-2 cells
were seeded onto 12-well plates at a density of 1 × 105 and 1.5 × 105 cells per
well, respectively. A549 cells were then infected with Ad5, Adhz60 or AdUV at
an MOI of 1. The cells and cell culture samples were then collected at 6, 24,
36, 48, 72, 96 and 120 h post-infection. The cells were separated from the cell
culture media and discarded from each sample following centrifugation at
2000 RPM (350 RCF) at 4 °C for 5 min using a micromax RF refrigerated
microcentrifuge equipped with an IEC 851 rotor (Thermo Fisher Scientific,
Waltham, MA, USA). The cell fraction was resuspended in PBS and subjected
to 3 freeze and thaw cycles to release all Ads from the infected cancer cells.
Cell free media samples and lysed cell samples were titered to detect the
concentrations of Ads within each fraction respectively.
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Cytotoxicity Assay
Cells were seeded at a density of 3 × 104 (A549) or 4.5 × 104 (Saos-2)
cells per well onto 24-well plates and allowed to adhere overnight. Cytotoxicity
was assessed by crystal violet staining after 5 days [97]. Suspended cells
were aspirated and the adherent cells were then fixed via incubation with
3.7% formaldehyde for 25 min at room temperature (RT). Excess
formaldehyde was washed away using PBS. Cells were then stained using
1% crystal violet for 30 min at RT. Excess crystal violet was washed away
with water. These crystal violet stained wells were then scanned using an HP
Scanjet 4070 scanner (HP, Palo Alto, CA, USA). The remaining crystal violet
was then solubilized with a 2% SDS solution and the sample ODs were
measured at 590 nm using a Synergy HT Multi-Mode Microplate Reader (BioTek, Winooski, VT, USA). These OD values were then normalized to mocktreated cells converting each sample OD into the percent (%) cell viability by
the formula, cell viability % = (OD of treated cells / OD of mock-treated cells) ×
100.
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DNA Sequencing
DNA sequencing was performed at the University of Louisville
(Louisville, KY, USA) Genomics Facility using Ion Torrent PGM Sequencing
200 kit v2 and Ion Torrent PGM system. An Ion 314 v2 Chip was used for
loading the enriched Ion One Touch 200 ISP samples. Open source
integrated genomics viewer (IGV) software was downloaded to view these
DNA sequencing data. Mutations with low DNA sequencing error rates are
listed in Table 1.
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Lung Cancer Xenograft
Female athymic nude mice (NCr-nu/nu) were obtained from the
National Cancer Institute (Bethesda, MD, USA). Tumors were formed
following the subcutaneous injection (SC) of 5 × 10 6 A549 lung cancer cells
into the right flanks of NCr-nu/nu mice at 6 weeks of age. Ads were titrated on
HEK293 cells using the plaque assay to determine the plaque forming units
(PFU) for AdUV and AdGFP prior to intratumoral injection as described
previously [107]. Once palpable tumors were established and reached 30
mm3, mice were randomized into 2 treatment groups to receive 5 × 108 PFU
of AdGFP (n = 8) or AdUV (n = 7) suspended in 50 µL PBS every 3 days for a
total of 4 treatments (2 × 109 PFU) from days 6 to 15. Tumor volumes were
determined by externally measuring these tumors in 2 dimensions with a
caliper and calculated based upon the following equation, V = (L × W 2)/2,
where L is length and W is the width of the tumor as described previously [34,
35]. Eight mice were treated with AdGFP and 7 mice were treated with AdUV.
Animal experiments were performed according to the institutional guidelines
approved by the University of Louisville Institutional Animal Care and Use
Committee (IACUC, protocol # 11079, Louisville, KY, USA).
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Immunohistochemistry
Tumors were harvested 7 days following the fourth treatment and
embedded in optimal cutting compound (OTC; Sakura Finetek, Torrance, CA,
USA), and stored at -20 °C. Briefly, slides were air-dried and fixed in ice-cold
methanol at 4 °C for 20 min. The endogenous tissue peroxidase activity was
blocked by incubation in a 0.3% hydrogen peroxide 3% methanol solution for
30 min according to the Vectastain ABC protocol (Vector Laboratories,
Burlingame, CA, USA). These tissues were then blocked in SuperBlock
(Pierce Biotechnology, Rockford, IL, USA) for 45 min at RT. Sections were
incubated with the goat-anti-hexon polyclonal antibody (Millipore, Billerica,
MA, USA), diluted 1:800, overnight at 4 °C. These signals were amplified by a
biotinylated anti-goat IgG diluted 1:200 in conjunction with Vectastain avidinbiotin complex method kit (Vector Laboratories, Burlingame, CA, USA).
Visualization was achieved using 3,3-diaminobenzidine-tetrahydrochloride
(DAB) for 5 min at RT; DAB staining was terminated using water (ImmPACT
DAB peroxidase substrate; Vector Laboratories, Burlingame, CA, USA). All
antibodies were applied and diluted in SuperBlock. Slides were washed 3
times with PBS following the application of SuperBlock, primary antibody,
secondary antibody and the ABC reagent. Biotinylated secondary antibody
and ABC reagents were both applied to slides for 1 h at RT. Slides were
counterstained with hematoxylin and photographed at 200× and 400×
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magnifications using an Olympus BX53 microscope (Olympus, Center Valley,
PA, USA).
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Statistical Analysis
All experiments were repeated at least 3 times. Quantification of results
were reported as the mean of 3 independent experiments plus or minus (±)
the SD. Statistical significance was set at p-value less than 0.05. Statistical
significance was assessed using two-way analysis of variance (ANOVA) test
and the log-rank sum test. Multiple comparisons were corrected for by
Bonferroni’s method. Therefore, all p-values reported from two-way ANOVA
were adjusted using this approach. Multiple comparisons were not made for
the log-rank sum test, therefore this p-value was not adjusted. All statistical
tests were conducted using GraphPad Prism 6 software (Microsoft, Redmond,
WA, USA).
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3.3 – Results
AdUV with Wild-type E1 and Mutated E3
As described in Chapter II, AdUV was isolated following the repeated
UV irradiation of dl309 (Ad5) which is an E1 wild-type, E3-deleted Ad [95,
108]. The irradiated viral progeny were then subsequently selected within
cancer cells to isolate AdUV [82]. In order to determine the mutations that
may be responsible for the improved cancer therapeutic efficacy of AdUV,
viral DNA was purified and sequenced as described in the methods. The E1
and E3 sequences of AdUV were shown to match the Ad5 genome, validating
Ad5 as the parental strain of AdUV. Twenty-five AdUV mutations with a low
error rate of sequencing (≤15%) are listed in Table 1 (GENEID#
AC_000008.1). Thirteen of these 25 mutations were either located within
introns or did not alter the coded amino acid sequences of their respective
genes. Therefore, this chapter will focus upon those 12 mutations which were
shown to alter their respective coded amino acid sequences in the AdUV
genome relative to Ad5 reference sequences (Table 1 and Figure 8).
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Reprinted with permission: Wechman et al., Viruses, 2016

Figure 8. DNA mutations contained in AdUV. Map of the 12
mutations in the AdUV genome which altered their respective
encoded amino acids. Ads: adenoviruses; pTP: precursor terminal
protein; DBP: DNA-binding protein.
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Site

Gene

Mutation

aa changed?

Non-conservative mutation?

4952

IVa2

G to C

T to S

No, T and S are both polar uncharged aa

8783

pTP

G to A

R to L

Yes, R is basic (+) and L is hydrophobic

11284

52K

T to C

Y to H

Yes, Y is hydrophobic and H is a positivity charged aa

12728

Intron

SN deletion

No

No

15829

pIII

G to A and lost 13 aa: IVSPRVLSSRTF

Yes, lost 13 aa

SN deletion,
non-sense mutation

61

16588

pV

G to A

No

No

17387

pV

G to C

G to R

Yes, G is hydrophobic and R is basic (+)

18755

pVI

SN deletion

No, targeted only the last codon.

No

Did not remove the codon stop
19483

Hexon

T to A

No

No

19513

Hexon

T to A

No

No

19657–8

Hexon

DN substitution, GA to AG

AT to AA

Yes, T is polar uncharged and A is hydrophobic

20378

Hexon

T to C

L to V

No, both L and V are hydrophobic

21163

Hexon

C to T

No

No

21630

Hexon

G to A

R to Q

Yes, R is basic (+) and Q is polar uncharged
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25995

100K

A to T

No

No

26561

Intron

G to A

No

No

26727–32

33K

Six-nucleotide deletion

Lost 2 aa A and A

Yes, lost 2 aa

27161

Intron

C to T

No

No

27314

pVIII

C to A

No

No

27339

pVIII

T to C

No

No

27650–1

pVIII

DN substitution TC to CT

RP to RS

Yes, P is cyclic and S is polar uncharged

28120

Intron

T to C

No

No

28596–601

E3 CR1-α0

Six-nucleotide deletion

Lost 2 aa I and G

Yes, lost 2 aa

29750

E3A 10.5kD

T to G

M to R

Yes, M is hydrophobic and R is basic (+)

35776

Intron

A to C

No

No

Reprinted with permission: Wechman et al., Viruses, 2016

Table 1. Table of AdUV mutations, their location, and changes in amino acid sequences. Conservative mutations
are defined as changes to the encoded amino acids which have led to similar biochemical properties. We were
interested in those non-conservative mutations in which DNA mutations altered the biochemical properties (charge,
hydrophobicity and size) of these coded amino acids. Within the table, blue rows indicate mutations to DNA binding and
packaging genes, green indicate mutations to Ad structural genes. White rows are indicative of mutations which were
either conserved or occurred in genes which do not have functions related to Ad structure or DNA binding. These
mutations were shown to have a low DNA sequencing error. The total Ad genome is 36 kilobases (kb). aa: amino acid;
DN: double nucleotide; SN: single nucleotide.
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Mutations That Affect Ad Packaging
There are several mutations in genes associated with virus packaging
(Figure 8 and Table 1, highlighted in blue). Mutation at position 4952 changed
the encoded threonine amino acid to a serine in the IVa2 gene, which is
associated with virus DNA packaging and the transcriptional activation of the
major late Ad promoter [109, 110]. AdUV was previously shown to rapidly
transition from early to late gene expression [82]. While both threonine and
serine serve very similar biochemical functions, the pivotal role of IVa2 to
package the Ad genome indicates the potential relevance of this mutation. Since
threonine and serine are both polar uncharged amino acids with very similar
structures, this mutation is conservative. It is possible however that this mutation
may have altered the tertiary or quaternary structure of IVa2 by replacing
threonine with a smaller serine residue.
The Ad terminal protein or pTP was mutated at position 8783 (Table 1 and
in Figure 8). The pTP peptide is the precursor form of the Ad terminal protein,
which matures following protease cleavage [111]. pTP stabilizes the origins of Ad
DNA replication, promoting DNA synthesis by the formation of a pTP/pol dimer
and the recruitment of the transcription factors octamer-binding protein 1 (Oct-1)
and nuclear factor I (NFI), which bind pTP and pol, respectively [112, 113]. In
AdUV, pTP is mutated at 8783, changing an encoded arginine with a positive
charge at physiological pH to a hydrophobic leucine.
A mutation at position 11284 to 52K replaced a hydrophobic tyrosine
residue with histidine, an amino acid with a positive charge at physiological pH
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(Table 1 and in Figure 8). The 52K protein is a DNA binding protein [114, 115].
Positively charged amino acids at residues 105, 106, and 107 were essential for
52K function [116]. Therefore, it is possible that the addition of more positively
charged amino acids may have further enhanced these functions.
In AdUV, the pV gene was mutated at 2 sites: 16588 (silent mutation) and
17387. The mutation at 17387 changed the endogenous glycine amino acid to an
arginine residue (Table 1 and in Figure 8). Glycine has a single hydrogen atom
as a side-chain, while arginine has a large, 6-carbon nitrogenous side-chain with
a positive charge at physiological pH. The endogenous function of pV is to form a
shell surrounding the condensed Ad DNA during virion packaging onto the
interior surface of the capsid during virion assembly by interaction with pVI and
p32 [117-119]. The DNA binding functions of pV has been described as histonelike in infected cells [120]. There are 16 known pV DNA binding sites, however,
the DNA binding sites of pV may be altered by the interaction with pVI, pVII, or μ
[121]. These pV peptide DNA binding sites were identified via PONDR-FIT,
version VL-XT [122]. This mutation (17387) replaced the 281 glycine residue with
an arginine which is not located in a known pV DNA binding site [120]. Therefore,
the substitution of the glycine hydrogen atom side-chain for the positively
charged arginine may have generated a novel site for pV to bind the negatively
charged DNA sugar-phosphate backbone with greater affinity. This could
promote viral packaging, leading to greater progeny production and increasing
the oncolytic efficacy of AdUV.
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A mutation was also observed at 26727–32, which deleted 6 DNA
nucleotides, removing 2 encoded alanine residues from 33K (Table 1 and in
Figure 8). The 33K protein is known to play a role to assist in Ad DNA packaging,
the transactivation of IIIa and pVI, and to serve as an alternative RNA splicing
factor [123, 124]. Furthermore, mutant viruses with 33K deleted were shown to
produce empty Ad capsids devoid of Ad DNA, demonstrating the requirement of
33K expression to efficiently package Ad DNA [124]. 33K has also been shown
to form a dimer with IVa2 to upregulate the transactivation of the major late Ad
promoter, which helps to promote virion assembly and release [110, 125].
The effect of these mutations maybe to cooperate to bind and package Ad
DNA more effectively and stimulate the rapid progression of AdUV from the early
to late stages of Ad replication via enhanced Ad major late promoter
transactivation.
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Mutations Affecting Other Ad Structural Proteins
There were also several mutations in other virus structural proteins (Table
1 and Figure 8, highlighted in green). A single nucleotide deletion in pIII at 15829
resulted in a premature stop codon, preventing the translation of 12 amino acids
(560–571, IVSPRVLSSRTF) into the pIII peptide (Table 1). The pIII gene has
also been implicated for its role to package Ad DNA [126]. Once expressed, pIII
binds with 4 other pIII macromolecules to form the penton base, which is located
at each of the 12 vertexes of the icosahedral Ad capsid [127]. Ad serotype 2
encoded pIII peptide (98.6% similarity to Ad5 by BLAST peptide analysis) was
shown to be the most highly phosphorylated peptide in the Ad2 phosphatome
with 12 total phosphorylation sites: one tyrosine, one threonine and 10 serine
residues [128]. This truncated form of pIII expressed by AdUV may form smaller
pIII pentamers (penton) with fewer phosphorylation sites.
Three of 6 mutations in hexon protein changed their respective amino acid
sequences (Table 1 and Figure 8). The mutations at 19657–8 changed a polar
uncharged threonine into an alanine, the mutation at 20378 changed a leucine to
a valine, and the mutation at 21630 changed the positively charged arginine to a
smaller, polar uncharged glutamine residue (Table 1 and Figure 8). Hexon is one
of the principal components of the Ad capsid. Each facet of the Ad capsid
contains 12 hexon trimers with hexon pentamers positioned at each vertex of the
icosahedral capsid [129, 130]. In vivo, hexon is highly immunogenic [131] and
contains many hypervariable regions (HVRs) which when bound by antibodies,
neutralize the infectivity of Ads [132]. Hexon contains nine HVRs located in the
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DE1 and FG1 loops between the coded 126 and 461 amino acids [132]. The
mutations located at 20378 and 21630 are not contained within 1 of these 9
HVRs. The 19657–8 mutation changed a threonine residue to an alanine at
position 273; however, this mutation is also not located within any of these 9
hexon HVRs. Therefore, these mutations should not alter the coded amino acids
of

the

hexon

HVRs.

However,

these

mutations

effects

upon

hexon

immunogenicity in vivo are unknown at this time.
One mutation in pVIII at 27650-1 altered the endogenous hydrophobic,
cyclic proline amino acid to a polar, uncharged serine residue (Table 1 and
Figure 8). Proline is the only known cyclic amino acid. Therefore proline is
required for the formation of sharp turns or kinks during polypeptide folding [133].
The capsid protein pVIII is known to interact with pV on the interior of the Ad
capsid, which together with pVI, helps to connect the Ad capsid vertexes to the
interior of capsid and ultimately to the Ad DNA genome as virions are assembled
[134]. The pVIII peptide contains several proline residues, from 37 to 90, which
forms a tight α-helical structure which interacts with hexon [134]. There are also
pVIII proline residues which contribute to the U-bend and α-helix structures [134].
This AdUV mutation substituted a proline for a serine at residue 160. However,
this mutation did not occur within these crucial α-helical (37–90) and U-bend (63–
77) proline-rich domains. Therefore, this mutation may not have affected the
polypeptide folding of pVIII as I expected. This mutation may have brought pVIII,
pV and pVI into a more open conformation or increased the affinity of the capsid
for Ad DNA, leading to greater oncolysis and spread in solid tumors.
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AdUV Displayed Greater Oncolysis and Release from A549 and Saos-2
Cells
As AdUV contains wild-type E1 region expression, therefore the ability of
AdUV to lyse cancerous and non-cancerous cells was determined. MRC5 noncancerous lung fibroblasts, HBEC non-cancerous lung epithelial cells, and A549
lung cancer cells were treated with AdUV, the non-selective Ad5, and the cancer
selective (E1b-deleted) Adhz60 at an MOI of 10. Cell viabilities were determined
via crystal violet staining after 72 h. Ad5 was shown to lyse MRC5 and HBEC
non-cancerous lung cell lines more effectively than Adhz60 (p-value < 0.001) and
AdUV (p-value < 0.001; Figure 9). While AdUV lysed significantly fewer HBEC
cells than Ad5, AdUV may lyse normal lung tissue in vivo. It seems unlikely as
that AdUV would lyse a significant number of lung cells, as Ad5-based oncolytic
Ads have not been shown to induce pulmonary toxicity clinically. AdUV, like Ad5,
lysed A549 lung cancer cells more effectively than Adhz60 (p-value < 0.01;
Figure 9). Therefore, AdUV kills lung cancer cells efficiently, indicating that these
AdUV mutations may have enhanced its oncolytic potential.
The effect of AdUV upon A549 and Saos-2 cancer cell viability was
determined by crystal violet staining following treatment with the indicated Ads for
5 days. A549 cells support greater Ad replication relative to Saos-2 cells [31].
A549 cells displayed the greatest differences in cell viability at an MOI of 1; these
viabilities were 91%, 40%, 67%, and 10% for AdGFP, Ad5, Adhz60, and AdUV,
respectively (Figure 10A). Saos-2 cells displayed the greatest differences in cell
viability at an MOI of 3: the viabilities were 100%, 74%, 87%, 57% for AdGFP,
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Ad5, Adhz60, and AdUV, respectively (Figure 10B). These data indicated that
AdUV displayed enhanced lysis of both A549 and Soas-2 cells. The enhanced
oncolytic effects of AdUV in Soas-2 cells, the cell line used to select AdUV,
relative to the parental strain Ad5.
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Reprinted with permission: Wechman et al., Viruses, 2016

Figure 9. AdUV displays similar cancer selectivity to Adhz60 in A549
lung cancer cells relative to HBEC and MRC5 non-cancerous lung
cells in vitro. A549 lung adenocarcinoma, MCR5 non-cancerous lung
fibroblast and HBEC non-cancerous lung epithelial cells were infected
with the indicated Ads at a multiplicity of infection (MOI) of 10 for 3 days.
They were then fixed with formaldehyde and stained using crystal violet.
These results were then quantified and expressed as the percentage cell
viability. Data were then analyzed using two-way ANOVA with multiple
comparisons corrected for by Bonferroni’s method. ‡, indicates p-value <
0.001.
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Reprinted with permission: Wechman et al., Viruses, 2016

Figure 10. AdUV displays greater oncolysis than Ad5 and Adhz60 in
A549 and Saos-2 cancer cells. (A) A549 and (B) Saos-2 cells were
infected with the indicated viruses and MOIs for 5 days prior to crystal
violet staining. The ODs of these treated cells were normalized relative to
non-treated cells.
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To study AdUV release from cancer cells, A549 and Saos-2 cancer cells
were infected with AdUV, Ad5, or Adhz60 at an MOI of 1. Six h after infection,
these cells were washed with fresh culture media prior to collecting 25 µL of the
cell culture media every 24 h for 5 days. These samples were then titered on
HEK293 cells using the TCID50 approach. The titer of each Ad was shown to
increase with time in both A549 and Saos-2 cancer cell lines (Figure 11A,B).
AdUV displayed higher viral titers than Ad5 and Adhz60 at each time point in
A549 and Saos-2 cells. At 72 h, Ad media titers were 5.9 × 108, 8.73 × 107, 2.18
× 107 for AdUV, Ad5, and Adhz60 treatments respectively (Figure 11A). At 72 h,
the titer of AdUV in the cell culture media was 10 fold greater than Ad5 and 30
fold greater than Adhz60. AdUV also displayed higher titers in Saos-2 cells than
Ad5 and Adhz60. At 72 h, AdUV titer was 2.28 × 106, while titers of Ad5 and
Adhz60 titers were 5.60 × 105 and 2.19 × 105, respectively (Figure 11B). These
data indicate that AdUV is released from both A549 and Soas-2 cancer cells
much more rapidly than Ad5 and Adhz60.

72

Reprinted with permission: Wechman et al., Viruses, 2016

Figure 11. AdUV displays greater release than Ad5 and Adhz60 in
A549 and Saos-2 cancer cells. (A) A549 and (B) Saos-2 cells were
infected with the indicated Ads at an MOI of 1. Day 0 media samples
were collected 6 h post-infection; after these samples were collected,
cells were then washed with cell culture media to remove noninternalized Ad particles. Media samples were then collected every 24 h
for 5 days. These samples were then titered on HEK293 cells using the
median tissue culture infective dose (TCID50) method.
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AdUV Inhibits Tumor Growth in Nude Mice
The efficacy and safety of AdUV was further tested in vivo using an A549
subcutaneous athymic nude mouse (NCr-nu/nu) xenograft model. Once tumors
grew to 30 mm3, mice were randomized and treated via intratumoral (IT) injection
with 5 × 108 plaque forming units (PFU) of AdUV or the negative control AdGFP
every 3 days for a total of 4 treatments (Figure 12A). The length and width of
each tumor were measured using a caliper every 3 days. Mice treated with AdUV
exhibited significantly suppressed tumor growth. AdUV with 94% reduction in
mean tumor volume compared with mice treated with the control AdGFP vector
at day 51 (p-value < 0.001, Figure 12A). Furthermore, all AdUV treated mice (n =
7) survived until day 125 (p-value = 0.0005) while only 2 AdGFP treated mice (n
= 8) survived to that time point (Figure 12B). Representative photographs were
taken of mice treated with AdGFP or AdUV at day 51 to display the marked
qualitative

differences between

the

2 treatment

groups (Figure

12C).

Furthermore, weight loss or lethargy was not observed following AdUV treatment.
In addition, AdUV was shown to express the viral late protein, hexon, in A549
xenograft tumor sections 7 days after the final viral injection, which was not
detected in tumors treated with AdGFP (Figure 12D). These results indicate that
AdUV can be safely used in animals to suppress tumor growth.
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Reprinted with permission: Wechman et al., Viruses, 2016

Figure 12. The effect of AdUV upon A549 xenograft tumor growth
and nude mice survival. Xenograft tumors were formed following the
subcutaneous (SC) injection of 5 × 106 A549 cells into the right flank of
athymic nude mice (NCr-nu/nu). (A) Tumors were then intratumorally (IT)
injected with AdGFP or AdUV 4 times from day 6 until day 15 for a total
dose of 2 × 109 PFU; (B) Mice were sacrificed once tumors were greater
than 1000 mm3 in size. Data were expressed as the percent (%) of death
among each treatment groups across time; (C) Representative mice
treated with AdGFP and AdUV were photographed at day 51. Boxes
indicate the magnified (~3.2× total magnifications) right flanks of 2
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representative mice per treatment group; (D) Immunohistochemistry for
hexon expression in A549 tumors harvested 7 days after the final
injection.

Slides

were

photographed

at

200×

and

400×

total

magnifications respectively. Differences in tumor growth were assessed
by two-way ANOVA. Adjusted p-values were reported for multiple
comparisons via Bonferroni’s method at each time-point. Differences in
murine survival were determined using the Kaplan-Meier log-rank sum
test. * indicates p-value < 0.05, † indicates p-value < 0.01, ‡ indicates pvalue < 0.001.
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3.4 – Discussion
The goal of this study was to investigate which Ad genes may affect Ad
oncolytic efficacy, and therefore, may be modified and combined with other
approaches for the development of future oncolytic Ads. The Ad early genes in
AdUV, E1a and E1b, E2, and E4, remained unchanged however, some critical
Ad late genes were mutated and are worthy of additional study. These AdUV
mutations likely enhanced Ad-mediated cancer cell lysis and cancer selectivity.
Twelve of these mutations in the AdUV genome of interest were shown to alter
the encoded amino acids, 5 of these mutations occurred within Ad capsid
structural genes (pIII, Hexon, pVIII). Another 5 mutations occurred within genes
encoding DNA binding or DNA packaging proteins (IVa2, pTP, 52K, pV, 33K).
Two mutations, E3A 10.5kD and E3 Cr1-α0, were not discussed in detail, which
may have affected the receptor internalization and degradation (RID) pathways
and immune cell–cell interactions, respectively.
The absence of mutations in the Ad early genes, E1 and E4, was
surprising as these genes have important roles in an array of virus–host
interactions. By far, the development of cancer selective Ads has focused upon
the modification of the Ad early genes by the introduction of deletions to E1b-19K
and E1b-55K or the regulation of E1a expression using cancer-selective
promoters [34, 135]. However, these data indicate that the late gene-encoded
structural proteins may also influence Ad replication, release, and oncolysis
[136]. This hypothesis agreed with a previous report showing that a mutation to
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Ad5 at 8350 was associated with large plaque formation in cancer cells due to
the truncation of 21 amino acids in a gene called i-leader [60].
In this chapter, mutations in 6 different Ad proteins with known roles to
package viral DNA during virion maturation are described. These Ad capsid
proteins include IVa2, pTP, 33K, pV, 52K and pVIII. In particular, pV, IVa2, pVI
and pVIII interact with and anchor Ad DNA onto the capsid [137]. The mutations
in pVIII, pV and IVa2 are all on the interior of the Ad capsid and have been
shown to cooperate to facilitate the packaging of DNA into the Ad capsid to
produce mature virions. The mutations occurring within pV, and its interaction
partners IVa2 and pVIII, indicate the importance of these proteins for DNA
packaging which could support the rapid release of Ads.
AdUV was shown to rapidly transition from early to late phase gene
expression as indicated in figure 4A [82]. IVa2 and 33K form a complex to
stimulate the transcription of the major late Ad promoter [110, 125]. It is possible
these IVa2 and 33K mutations found in AdUV may have increased the formation
of this complex to induce early to late phase transition during Ad replication.
Furthermore, there exists indirect evidence that IVa2 and 33K can also form a
complex with DNA-binding protein (DBP) on one of the Ad capsid vertexes,
facilitating Ad DNA packaging [110]. These mutations acting together may be
associated with rapid AdUV virus assembly and release.
These results also indicate that AdUV can be safely used in animals and
suppress tumor growth. AdUV is an E1b wild-type Ad. In early oncolytic studies
in the 1950s, wild-type Ads were the first viruses used in clinical trials [138].
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However, wild-type Ads are no longer used in clinical studies because of safety
concerns and their limited cancer therapeutic efficacy. For this reason, AdUV,
which is based on wild-type Ad5, is unlikely used in future clinical studies.
Therefore, the goal of this limited animal study to investigate whether these novel
AdUV mutations were toxic to animals. To study these mutations further, each
mutation should be individually introduced into a well-characterized Ad vector
background to understand their impact upon Ad replication and oncolytic therapy.
The expression of E1b by AdUV also likely enhanced its oncolytic
potential. Several E1b wild-type oncolytic vectors have been described in the
literature with increased cancer therapeutic efficacy containing other modes of
cancer selectivity such as cancer selective promoters, or partial E1a deletions
[81, 139]. Even though E1b expression is not essential for Ad replication in
cancer cells [31], E1b may enhance the efficiency of Ad replication in cancer
cells, likely via cyclin E induction [31]. Recently published data, shown in chapter
II, indicates that E1b upregulates autophagy; however, the mechanism of
autophagy induction by E1b remains unknown [82]. Autophagy is known to
degrade intracellular components, organelles and long-lived proteins [140-142]. It
appears that E1b may drive Ad-mediated autophagy induction to promote virus
replication by generating nutrient to build virus particles [55, 66]. Therefore, the
oncolytic effects and replication of AdUV was likely enhanced by E1b.
These findings taken together provide additional insight into the
construction of oncolytic Ads. It appears that E1b expression and mutations in
the Ad late proteins, especially those associated with genome packaging, may
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augment Ad release and spread within tumor tissue, leading to enhanced
oncolytic therapy efficacy. One of the limitations of this study is that the specific
effects of these mutations upon oncolytic replication are unknown at this time. It
is also possible that several of these mutations may cooperate to enhance
oncolytic Ad efficacy.
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CHAPTER IV
THE ROLE OF JNK PHOSPHORYLATION AS A MOLECULAR TARGET TO
ENHANCE ADENOVIRUS REPLICATION, ONCOLYSIS AND CANCER
THERAPEUTIC EFFICACY
4.1 – Introduction
Oncolytic Ads represent an emerging class of lung cancer therapeutics
with clear cancer selectivity in vitro [33, 55, 90]. E1b-deleted Ads selectively lyse
cancer cells very efficiently in vitro; however, these viruses were ineffective
during clinical trials [19, 53, 143, 144].
To overcome the limitations of Ad therapy, a more complete
understanding of Ad-mediated cancer cell lysis or oncolysis is necessary. Among
the programmed cell death pathways (apoptosis, necrosis, and autophagy),
autophagy inducers have been reported to support Ad replication and oncolysis
[66, 77]. Therefore, autophagy is of significant interest as a potential driver of Ad
oncolysis. Many viruses interact with autophagy signaling during infection,
however autophagy can inhibit or promote virus replication. For example,
autophagy inhibits HIV-1 [145], HSV [146] and influenza A infection [147].
However, Ads induce autophagy to promote their own replication and to lyse
cancer cells [66], indicating that Ads induce autophagy to produce their antitumoral effects [77]. Furthermore, the autophagy inhibitors 3MA and Baf-A1
inhibited Ad replication and protect cancer cells from Ad oncolysis [66, 78].
Previously, E1b-deleted Ads were shown to induce less efficient production of
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the autophagy markers LC3-II and p62 [34, 66]. Therefore, E1b may play a role
as an autophagy inducer.
The field of

oncolytic adenovirology

has not emphasized

the

investigation of autophagy and its induction by E1b. Therefore, the effect of
various autophagy signaling pathways upon the replication or oncolytic effects of
E1b-deleted Ads is unknown. Autophagy induction occurs predominantly via 2
mechanisms: 1) glucose starvation 2) phosphoinositide 3-kinase (PI3K) and MAP
Kinase (MAPK) signal transduction. Autophagy induced via glucose starvation is
driven by the energy-sensor AMP-activated protein kinase (AMPK) which
promotes

autophagy-mediated

cellular

catabolism

[148,

149].

AMPK

phosphorylates Ulk1 at serine 317 and 777, activating Ulk1 leading to
autophagy induction [148]. mTOR disrupted AMPK coordinated Ulk1
phosphorylation and phosphorylates Ulk1 at serine 757 to inhibit autophagy
[74]. Furthermore, rapamycin treatment (an mTOR inhibitor) enhanced E1bdeleted Ad replication and oncolysis. Studies have indicated that mTOR
activation is dependent upon the E4-ORF4 protein phosphatase 2A-binding
domain and that mTOR supports the S-phase entry of G0-phase primary cells
[150]. In this way, E4-ORF4 is thought to enhance Ad replication.
Interestingly, Ads do not appear to induce autophagy via the cell
starvation AMPK pathway. Preliminary studies indicated that E1b wild-type
Ads induce autophagy via c-JUN n-terminal kinase (JNK) phosphorylation, which
occurs independently of the AMPK/mTOR-induced cell starvation autophagy
induction pathway [77, 81, 151]. JNK induces autophagy via the phosphorylation
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of BCL-2, activating BECLIN-1 [36, 81, 152]. JNK and the map kinase (MAPK)
pathway may play a crucial role to upregulate ATG5 expression [153]. The first
report, to my knowledge, to demonstrate that Ads induced JNK phosphorylation
via E1b was published by See and Shi in 1998; however, this report did not
indicate if Ad induced p-JNK to enhance Ad replication or oncolysis [80]. Klein et
al. reported that JNK expression was essential for the E1b wild-type Ad,
Δ24RGD, to induce autophagy in vitro and in vivo [81]. The goal of this chapter
was to characterize the induction of p-JNK by E1b-deleted Ads and the role of pJNK to stimulate Ad replication and cancer cell oncolysis.
Ads have been shown to manipulate both apoptosis and autophagy via
the expression of E1a, E1b-19K, and E1b-55K to lyse cancer cells in a highlycoordinated manner. E1A is known to stabilize TP53 inducing apoptosis [96],
while E1b-19K and E1b-55K counter act these effects by antagonizing BAK/BAX
and TP53 respectively. Simultaneously, E1b-19K and E1b-55K also stimulate
MKK7-mediated JNK phosphorylation to induce autophagy [80, 154]. Therefore,
E1b expression appears to drive Ad oncolysis towards an autophagy-mediated
mechanism; however, the effects of E1a upon JNK phosphorylation remains
unknown. Interestingly, E1b-deletions are not sufficient to completely abolish
JNK phosphorylation by oncolytic Ads, implicating the role of E1a as an inducer
of both apoptosis and JNK phosphorylation.
In this chapter, the ability of oncolytic Ads to induce JNK phosphorylation
via E1a or E1b was assessed using Ads which selectively over express E1a and
Ads with selective E1b-deletions in lung cancer cells. These data indicated that
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both E1b and E1a were crucial for efficient JNK phosphorylation in A549 lung
cancer cells. To determine in p-JNK inducers enhanced Ad replication and
oncolysis, known chemical p-JNK inducers were screened to determine which
drug was the most effect p-JNK inducer in A549 cells; this drug (etoposide) was
then used in combination with the previously developed oncolytic Ad AdUV [82,
136]. These data indicated that etoposide enhanced AdUV oncolysis; however,
etoposide was not shown to enhance AdUV replication using these conditions. It
is expected that etoposide induced p-JNK production via a non-specific
mechanism of action. Therefore, the selective effects of JNK activation upon
oncolytic Ad replication and oncolysis was assessed using siRNA, targeting both
JNK1 and JNK2 mRNAs sequences [155, 156]. The suppression of JNK1/2 was
shown to protect cancer cells from Ad-mediated A549 cell lysis. Ad replication
was also significantly repressed in JNK1/2 siRNA-transfected cells infected by
the E1b-19K wild-type Ads Ad5 and Adhz63, but not the E1b19K-deleted Ad
Adhz60. These studies have demonstrated for the first time that p-JNK is not only
essential for Ad oncolysis, but also for Ad replication. These data suggest that
JNK is an intriguing molecular target to enhance the therapeutic effects of
oncolytic Ad therapy.
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4.2 – Materials and Methods

Cell Lines and Culture Conditions
HEK293 (ATCC no. CRL-1573) human embryonic kidney and A549
(ATCC no. CCL-185) human lung carcinoma cells were purchased from the
ATCC (ATCC, Rockville, MD, USA). A549 and HEK293 cells were maintained in
DMEM supplemented with 10% fetal bovine serum, L-glutamine, and
penicillin/streptomycin (100 U/mL). All other cell culture reagents were obtained
from VWR (VWR, Radnor, PA, USA). All cells were cultured and maintained in
humidified 5% CO2 incubators at 37 °C.
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Adenoviral Vectors
Ad5 dl309 is E1 wild-type E1 [95] and was used as a non-selective Ad
control in these studies. Adhz63 is an E1b55K-deleted Ad similar to dl1520 and
H101 and was used as a cancer selective control [96]. Adhz69 is an E1b55Kdeleted Ad that over-expresses E1A via the CMV promoter [157]. Adhz60 is an
E1b55K, 19K-deleted vector used as a cancer selective control and E1b19Kdeleted Ad control for these studies [96]. AdUV is an E1b wild-type mutant
oncolytic Ad based upon Ad5 as described previously [82, 136]. AdGFP is E1
(E1a and E1b) deleted, with green fluorescent protein (GFP) expression driven
by the CMV promoter [55]. AdGFP, as a negative control, does not replicate nor
induce CPE [34, 35]. All Ads used in this study are based upon Ad5 backbone
sequences (GENEID# AC_000008.1).
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Plasmid amplification and transfection
To chemically transform a plasmid into chemically competent bacteria, the
bacteria were mixed with between 200 ng and 1 μgs of plasmid DNA on ice for
30 min. The mixture was then transferred into a 42 °C water bath for 30 s. After
the heat shock, the bacteria/plasmid mixture was returned to the ice for 2 min.
250 μL of SOC media (Corning Cellgro, Tewksbury, MA) was then added to the
mixture and placed at 37 °C for 1 h. This mixture was plated on LB agar plates
containing 100 µg/mL of ampicillin. The plates were incubated at 37 °C overnight.
Colonies were selected the next day and grown in LB broth media, again
supplemented with the proper antibiotic at the correct final concentrations listed
above, and once again incubated overnight at 37 °C in a shaker set at 300 RPM.
After the colonies were expanded and grown in LB media, these cultures were
then processed to isolate DNA plasmids using Qiagen Mini, or Maxi-scale kits
(Qiagen, Hilden, Germany). Mini-scale cultures utilized 3-5 mL of 100 µg/mL
ampicillin containing Luria-Bertani (LB) broth, while Maxi-scale cultures utilized
250-500 mL of 100 µg/mL ampicillin LB broth. The entire culture was then
pelleted using an AvantiJ-26XPI centrifuge (Beckman Coulter, Brea, CA, USA)
spun at 8000 xg for 3 (Mini-scale) to 15 (Maxi-scale) min respectively. Following
centrifugation, the media were decanted and the entire pellet was resuspended
in RNAseA containing P1 buffer provided by the kit. The plasmid extraction and
purification steps from this point forward were carried out in accordance with the
manufacturer’s protocol (Qiagen, Hilden, Germany).
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Two plasmids were used during the completion of these studies. The
CMV-E1b19K plasmid was a generous gift from Dr. Eileen White at Rutgers
University [158]. The pCycE-GFP plasmid was constructed by Dr. Heshan Zhou
at the University and Louisville and was used as a negative control; pCycE-GFP
was also used to determine plasmid transfection efficiency [31]. 2 × 105 A549
cells were seeded onto 6-well plates overnight for transfection. Cells were 6070% confluent the next day; however, small gaps were present between those
cells, ensuring maximal transfection efficiency. These cells were then transfected
with 2 µg of plasmid DNA using Jetprime according to the manufacturer’s
protocol for DNA transfection. The media of these transfected cells were
changed after 4 h. Using these conditions, a transfection efficiency of at least
85% was observed.
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Drug preparation
Etoposide, cytrabine, cycloheximide, and paclitaxel were all purchased
from sigma (Sigma-Aldrich, St. Louis, MO, USA) and diluted into 100% DMSO at
a stock concentration of 10 mM. These stock solutions were then diluted in
serum-containing media to 1 mM for use at the indicated micromolar (µM)
concentrations indicated. Drug treatments were applied to the cells in culture
briefly following cell seeding, but prior to Ad infection for the combination studies.
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SiRNA transfection
To ascertain the role of JNK expression upon Ad replication and oncolysis,
siRNA transfection was utilized. Both JNK1 and JNK2 are phosphorylated by
Ad5, therefore the suppression of both JNK1 and JNK2 was necessary [81]. The
JNK1/2-siRNA utilized in this study: JNK1/2 5’- AAAGAAUGUCCUACCUUCU-3’
was initially described by Dr. Li in 2004 and targets JNK1 and JNK2 at the mRNA
positions 377 and 425 respectively [155]. JNK1/2-siRNA was ordered by email
using the sequence from Dr. Li and its duplex complement from Thermo Fisher
Scientific (Thermo Fisher Scientific, Waltham, MA, USA). The optimal siRNA
concentration to suppress JNK1 and JNK2 was assessed by transfecting A549
cells with 10 to 400 nM of JNK1/2-siRNA. These transfected cells were then
lysed and studied by Western blot analysis to determine whether efficient JNK1
and JNK2 protein production was suppressed. 120 µg of these protein isolates
were electrophoresed on 10% SDS-PAGE gels and JNK1 and JNK2 production
was probed using JNK1 (1:100) and JNK2 (1:200) selective antibodies from
Santa Cruz (Santa Cruz, Dallas, TX, USA).
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Virus Titration and Release
A549 cells were seeded onto 12-well plates at a density of 4 × 104 cells
per well and allowed to adhere overnight. Cells were then treated as indicated
and harvested with a cell scraper. These samples were then subjected to 3
freeze-thaw cycles to release all the Ads into solution for the determination of
total Ad titer by the median tissue culture infective dose (TCID50) method as
described in Chapter II.
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Western Blot Analysis
A549 cells were seeded onto 60 mm dishes overnight at a density of 3 ×
105 cells per dish. Cells were collected and centrifuged at 1500 RPM (453 RCF)
at 4 °C for 5 min using an Eppendorf 15 amp 5810R refrigerated centrifuge
equipped with a A-4-62 rotor (Eppendorf, Hamburg, Germany). The cell pellets
were then washed with PBS prior to lysis with RIPA buffer containing 50 mM
Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS
with PI containing 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), pepstatin
A,

trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane

(E-64),

bestatin,

leupeptin, and aprotinin (10 mL / 1 × 106 cells; Sigma, St. Louis, MO, USA). The
cell lysates were then incubated on ice in PI containing RIPA buffer for 30 min
and homogenized every 10 min using a vortex-genie 2 (Scientific Industries,
Bohemia, NY, USA). These lysates were then centrifuged at 14,500 RPM
(196,000 RCF) at 4 °C for 10 min using a micromax RF microcentrifuge equipped
with an IEC 851 rotor to pellet cell debris formed during lysate preparation
(Thermo Fisher Scientific, Waltham, MA, USA). The pellet was discarded and the
supernatant was stored at -80 °C for further experimentation. Protein
concentrations were determined using the Pierce BCA protein assay kit
according to the manufacturer’s instructions (Thermo Fisher Scientific, Waltham,
MA, USA). Equal amounts of cellular protein were resolved by electrophoresis
through 8% (E1A), 10% (JNK, p-JNK, JNK1, JNK2, E1b-19K, actin) or 12%
(LC3-I and LC3-II) SDS-polyacrylamide gels prior to transfer to methanol
activated PVDF membranes (GE healthcare, Little Chalfont, UK) using a semi-
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dry transfer apparatus (BIO-RAD, Hercules, CA, USA). Membranes were then
blocked using 5% nonfat milk prepared in TBST for 1 h at room temperature. To
detect protein expression, membranes were incubated with the following primary
antibodies: rabbit-anti-human-LC3 (1:3000; Novus Biologicals, Littleton, CO,
USA), rabbit-anti-human-actin (1:2000; Sigma, St. Louis, MO, USA), rabbit-antihuman p-JNK (1:1000; Cell Signaling, Danvers, MA, USA), rabbit-anti-humanJNK (1:1000; Cell signaling, Danvers, MA, USA), mouse-anti-human-JNK1
(1:100; Santa Cruz, Dallas, TX, USA), mouse-anti-human JNK2 (1:200; Santa
Cruz, Dallas, TX), mouse-anti-Adenovirus2-E1b19K (1:150; Calbiochem, San
Diego, CA, USA) or mouse-anti-adenovirus-E1A (1:1000; BD Pharmagen, San
Jose, CA, USA) at 4 °C overnight on a lab-line thermal rocker (Thermo Fisher
Scientific, Waltham, MA, USA). The mouse-anti-Adenovirus2-E1b19K antibody is
cross-reactive with Ad serotype 5 (Ad5). Primary antibody binding was detected
by the incubation with the horseradish peroxidase (HRP) linked anti-mouse or
anti-rabbit immunoglobulin (Ig) diluted 1:5000 for 1 h at room temperature
(Amersham, Piscataway, NJ, USA). All antibodies were diluted in TBST.
Enhanced chemiluminescence (ECL) reagents were used to detect HRP-linked
secondary antibody binding according to the manufacturer’s instructions
(Amersham, Piscataway, NJ, USA).
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Cytotoxicity Assay
A549 cells were seeded at a density of 2 × 104 cells per well onto 24-well
plates and allowed to adhere overnight. Cytotoxicity was assessed by crystal
violet staining at the time-points indicated [97]. Suspended cells were aspirated,
and the adherent cells were then fixed via incubation with 3.7% formaldehyde for
25 min at room temperature (RT). Excess formaldehyde was washed away using
PBS. Cells were then stained using 1% crystal violet for 30 min at RT. Excess
crystal violet was washed away with water. These crystal violet stained wells
were then scanned using an HP Scanjet 4070 scanner (HP, Palo Alto, CA, USA).
The remaining crystal violet was then solubilized with a 2% SDS solution, and the
sample ODs were measured at 590 nm using a Synergy HT Multi-Mode
Microplate Reader (Bio-Tek, Winooski, VT, USA). These OD values were then
normalized to mock-treated cells, converting each sample OD into the percent
(%) cell viability by the formula, cell viability % = (OD of treated cells/OD of mocktreated cells) × 100.

94

Statistical Analysis
All experiments were repeated at least 3 times. Quantification of results
was reported as means of 3 independent experiments plus or minus (±) the SD.
Statistical significance was set at p-value less than 0.05. Statistical significance
was assessed using the two-way ANOVA test for the EC50 combination ratio
study (Figure 18A) corrected for multiple comparisons via Bonferroni’s test. All
other statistical tests were conducted using one-way ANOVA with Tukey’s posttest for multiple comparisons. However, the statistical analysis of the p-JNK fold
changes induced by Ad5 treatment across time (Figure 13B,C) was conducted
using one-way ANOVA with Dunnett’s post-test. All statistical tests were
conducted using GraphPad Prism 6 software (Microsoft, Redmond, WA, USA).

95

4.3 – Results

Adenovirus serotype 5 induces p-JNK expression in A549 cells
To observe the effect of Ad infection upon JNK phosphorylation, A549
lung cancer cells were infected with the wild-type serotype 5 Ad (Ad5) at an MOI
of 10. Infected or non-infected (Mock) cells were then observed for CPE and for
the production of p-JNK via Western blot analysis from 18 to 72 h post-infection.
These data indicated that E1b wild-type Ads, such as Ad5, led to a timedependent induction of CPE and p-JNK; induced p-JNK production was began at
18 h (4.1 fold) reaching the greatest p-JNK production at 72 h (18.4 fold) postinfection (Figure 13A-C). The highest levels of p-JNK production (48, and 72 h)
was associated with changes in A549 cell morphology consistent with CPE
(Figure 13A,C). To quantify the effects of Ad5 upon CPE and oncolysis, A549
cells were stained with crystal violet at the time-points indicated. These data
were expressed as a percentage of Ad5 treated cell viability relative to mock cells
at each time-point (Figure 13C). By plotting these fold changes in p-JNK and
LC3-II production overtime, the effects of Ad5 upon the induction of p-JNK (18 h)
occurred first, prior to the induction of LC3-II (36 h), A549 oncolysis, and CPE
induction by Ad5 at 48 and 72 h (Figure 13C). These data indicate that the E1b
wild-type Ad Ad5 induced JNK phosphorylation during A549 cell oncolysis. This
was especially evident during the late phases of infection at 48 and 72 h postinfection respectively.
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Figure 13. The effect of Ad5 upon JNK phosphorylation. A549 cells were
mock treated or infected with Ad5 at an MOI of 10 and then observed from 0 to
72 h post-infection. (A) CPE induced by Mock or Ad5 treatment in A549 cells was
observed at the indicated time-points. Pictures were taken using an inverted
microscope at 200x total magnification. 600 µm scale bar is located in the top
right corner. (B) A549 cell lysates were treated and harvested at the time-points
indicated and observed for protein production via Western blot analysis. (C)
Quantification of these Western blot data normalized to actin protein expression.
Cell viability was determined by crystal violet staining and plotted on the
secondary y-axis. Results are expressed as the average of 3 experiments plus or
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minus the standard deviation. Statistical analysis was performed using one-way
ANOVA by Dunnett’s test for multiple comparisons relative to the mock control (1
fold) column. * indicates p-value < 0.05, † indicates p-value < 0.01, ‡ indicates pvalue <0.001
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The effects of E1b upon p-JNK activation
To determine whether E1b-deleted Ads induced JNK phosphorylation, we
infected A549 cells with the E1b wild-type Ad5, the E1b55K-deleted Adhz63 and
the E1b55,19K-deleted Adhz60 at a MOI of 10 and observed for p-JNK
production by Western blot analysis. Differences in p-JNK production were first
assessed at 36 h post-infection prior to A549 cells lysis (Figure 14A). However,
no differences in p-JNK production were observed between E1b wild-type and
E1b-deleted Ad treatments at any of the 3 MOIs (1, 3, and 10) tested (Figure
14B,C). Therefore, the effects of Ad5, Adhz63 and Adhz60 upon p-JNK
production at 48 and 72 h post-infection were assessed. These data indicated
that p-JNK production by Ad5 (32.2 fold), Adhz63 (28.1 fold) and Adhz60 (10.9
fold) were significantly different at 72 h post-infection (Figure 15A-C).
Interestingly, Adhz63 was shown to induce similar p-JNK production to
Ad5 (28.1 fold vs. 32.2 fold respectively), while Adhz63 induced similar oncolytic
effects to Adhz60 at 72 hours (Figure 15C,D). These data indicate that E1b-19K
expression, via Adhz63, may be critical for inducing p-JNK production. Therefore,
a plasmid that expresses E1b-19K under control of the CMV promoter (CMVE1b19K) was utilized to selectively assess the role of E1b19K as a p-JNK
inducer (Figure 15E). These data indicated that E1b-19K expression was
sufficient to induce p-JNK production (22.7 fold) in A549 cells alone,
demonstrating the potentially critical role of E1b-19K to activate JNK signally
during Ad infection.
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Figure 14. The effect of selective E1b-deleted Ads upon p-JNK at 36 h. A549
cells were mock-treated or infected with Ad5, Adhz63, and Adhz60 at an MOI of
1, 3 and 10 respectively. (A) Crystal violet staining of A549 cells treated as
indicated at 36 h post-infection. (B) A549 cell lysates were prepared at 36 h postinfection and observed for the production of the indicated proteins via Western
blot analysis. (C) Quantification of these Western blot data was normalized to
actin protein expression. Results were expressed as the average of 3
experiments plus or minus the standard deviation.
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Figure 15. The effect of E1b-19K expression upon JNK phosphorylation.
A549 cells were mock treated or infected with AdGFP, Ad5, Adhz63 and Adhz60
at an MOI of 10. (A) CPE induction in mock, AdGFP, Ad5, Adhz63 and Adhz60
treated cells. Pictures were taken using an inverted microscope at 200x total
magnification at 48 and 72 h post-infection. 600 µm scale bar is located in the top
right corner. (B) A549 cell lysates were observed for the production of the
indicated proteins via Western blot analysis. (C) Quantification of these Western
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blot data normalized to actin protein expression. (D) Cell viability was determined
by crystal violet staining and expressed as the percent cell viability relative to
non-treated cells. (E) A549 cells were mock transfected, or were transfected with
GFP or CMV-E1b19K expressing plasmids as indicated. These cells were then
lysed and observed for the production of the indicated proteins. IOD is an
abbreviation for integrated optical density. IOD’s were determined via
densitometric analysis using Gel-pro analyzer 4.0 software. * indicates p-value <
0.05, † indicates p-values < 0.01
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The effect of E1a upon p-JNK production
While extensive research has focused upon the role of E1b as an inhibitor
of apoptosis, recent reports indicate that E1b is also required for JNK
phosphorylation; however, effects of other Ad genes upon JNK phosphorylation
is unknown [159]. E1a has been shown to induce JNK phosphorylation in murine
3T3 fibroblasts; however, the effect of E1A upon p-JNK in cancer cells following
oncolytic Ad infection remains unknown [159]. In this report, the total E1b-deleted
Ad Adhz60 did not display totally ablated p-JNK production (10.9 fold), indicating
that other Ad genes may also play a role to induce JNK phosphorylation (Figure
15C). Furthermore, E1b-deleted Ads have been shown to depend upon efficient
E1a expression to lyse cancer cells [29], implicating the role of E1A as a potential
inducer of p-JNK production during cancer cell oncolysis.
To assess the role of E1A as a p-JNK inducer, A549 cells were treated
with Ad wild-type Ad5, the E1b55K-deleted E1a wild-type Adhz63, and the
E1b55K-deleted CMV-E1a Adhz69. Therefore, by comparing between the
Adhz63 and Adhz69 treatment groups, the effects of increased E1a production
upon p-JNK is evident as both of these Ads have identical E1b55K-deleted
backgrounds. These data indicated that selective E1a over-expression by
Adhz69 lead to increased E1A and p-JNK production (39.9 fold) relative to Ad5
(12.4 fold) and Adhz63 (3.8 fold) in the absence of E1b-55K expression (Figure
16B).
E1A is a well-known transactivator of many Ad and host cell genes [160].
One of the transcriptional targets of E1A is E1b-19K [40], E1b-19K induces p104

JNK production in A549 cells as shown in Figure 15E. Therefore, the effects of
E1A over-expression upon E1b-19K protein production was observed to
determine if Adhz69 induced p-JNK production was due, at least in part, to
enhanced E1b-19K expression (Figure 16C). Ad5 and Adhz60 were used as
E1b-19K production positive and negative controls respectively for this
experiment. These data have shown that markedly enhanced E1A production by
Adhz69 is not significantly increase E1b-19K production relative to Adhz63 in
A549 cells (31.0 IOD vs. 20.1 IOD; Figure 16C). Therefore, E1a likely drives pJNK production via an E1b19K independent mechanism of action.
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Figure 16. The effect of E1a expression upon JNK phosphorylation. A549
cells were mock-treated or infected with AdGFP, Ad5, Adhz63, and Adhz69 at an
MOI of 10. (A) Cell viability was determined by crystal violet staining and
expressed as the percent cell viability relative to non-treated cells at 48 h postinfection. (B) A549 cell lysates were treated as indicated at 48 h post-infection
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and observed for the protein production of the indicated proteins via Western blot
analysis. (C) E1b-19K protein production was determined via Western blot
analysis. Adhz60 is E1b-19K deleted and was used as a negative control. IOD is
an abbreviation for integrated optical density. IOD’s were determined via
densitometric analysis using Gel-pro analyzer 4.0 software.
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Evaluating known p-JNK inducers as enhancers of Ad oncolysis
Four p-JNK inducing cancer chemotherapeutics (etoposide, cytarabine,
cycloheximide and paclitaxel) were evaluated for their p-JNK induction in A549
cells [83-86]. First, the effective concentration 50% (EC50) of each of these
drugs to lyse A549 cells were determined (Figure 17A). To evaluate which drugs
induced p-JNK production most efficiently, A549 cells were treated at their
EC50s for 24 h and then their effects upon p-JNK production were assessed via
Western blot analysis. These data indicated that etoposide and cycloheximide
induced p-JNK production; while cytarabine and paclitaxel did not induce p-JNK
using these conditions (Figure 17B).
These data led to additional studies to determine if etoposide or
cyclohexamide enhanced Ad replication and oncolysis. Using the median-effect
method of Chou and Talalay [161], the effect of etoposide and cyclohexamide
upon AdUV oncolysis was determined [82, 136]. Among these two drugs, the
oncolytic effects of AdUV was only enhanced following etoposide treatment in
A549 cells (p-value < 0.001) using the combination ratio of 0.5 MOI and 0.7 µM
respectively (Figure 17C). Upon further dose-escalation of this combination ratio,
the greatest differences in AdUV oncolysis were observed between AdUV alone
at an MOI of 1 (70%) and AdUV (1 MOI) in combination with etoposide at 1.4 µM
(54%; Figure 18A). Using these conditions, however, etoposide was not shown to
enhance AdUV replication (Figure 18B). These data indicated that the p-JNK
inducer, etoposide, was sufficient to enhance AdUV oncolysis but not AdUV
replication.
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Figure 17. The effect of etoposide upon p-JNK and Ad oncolysis. A549 cells
were treated with etoposide, cytrabine, cycloheximide and paclitaxel to determine
their EC50s in A549 cells. (A) EC50 values as determined using crystal violet
staining and prism statistical analysis. (B) The effect of these drugs at their
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EC50’s upon JNK phosphorylation was determined by Western blot analysis. (C)
Crystal violet staining for A549 cells treated with AdUV at 0.5 MOI alone, 0.7 µM
etoposide or in combination. Significance was assessed via one-way ANOVA
with Tukey’s post-test analysis for multiple comparisons. † indicates p-value <
0.01
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Figure 18. The effect of etoposide upon Ad replication and oncolysis. A549
cells were treated with etoposide and AdUV at a constant ratio of 0.5 MOI AdUV
to 0.7 µM etoposide, respectively. (A) Crystal violet staining of A549 cells treated
with the increasing combination ratios (1 to 5 fold) to determine if etoposide
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enhanced AdUV oncolysis. Significance was assessed via two-way ANOVA with
Bonferroni’s post-test analysis for multiple comparisons. (B) AdUV titer as
determined by the TCID50 method. Significance was assessed via one-way
ANOVA with Tukey’s post-test analysis for multiple comparisons. † indicates pvalue < 0.01, ‡ indicates p-value < 0.001.
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The selective effects of JNK upon Ad replication and A549 cell oncolysis
Wild-type Ad infection has been shown to induce JNK1 and JNK2
phosphorylation [80, 81]. Therefore, the suppression of both JNK1 and 2 using
siRNA was necessary to elucidate effects of JNK upon Ad replication and
oncolysis.
First, A549 cells were either mock treated or transfected with 10 to 400 nM
of JNK1/2-siRNA. Cells were screened for efficient JNK1/2 suppression via
Western blot analysis with JNK1 and JNK2 selective antibodies. Using this
approach, JNK1/2-siRNA selectively inhibited JNK1 and JNK2 expression at 200
and 400 nM respectively; the 400 nM transfection condition was selected as this
condition displayed the most efficient suppression of both JNK1 and 2 (Figure
19A). JNK1/2-siRNA transfection protected A549 cells against oncolysis relative
to scramble-siRNA transfected cells (Figure 19B). This protective effect was
observed for Ad5, Adhz63 and Adhz60. The greatest differences, however, were
seen in Ad5-infected cells (cell viability 29% vs. 61% scramble-siRNA vs.
JNK1/2-siRNA, respectively) and Adhz63-infected cells (cell viability 45% vs.
77% scramble-siRNA vs. JNK1/2-siRNA, respectively; Figure 19B). Using the
same siRNA transfection approach, JNK1/2 suppression was also shown to
inhibit the replication of all 3 Ads studied (Figure 19C). These differences were
observed for all 3 Ads however, only Ad5- and Adhz63- infected cells displayed
statistically significant differences between siRNA transfection groups. We found
that 1.45 × 108 and 6.6 × 107 titers when transfected with scramble-siRNA,
compared to 1.43 × 107 and 1 × 107 titers when transfected with the JNK1/2113

siRNA, respectively (Figure 19C). These data indicated that JNK expression
supports both the Ad replication and oncolytic effects of Ads in A549 cancer
cells.
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Figure. 19 The effect of JNK expression upon A549 cell oncolysis and
oncolytic Ad replication. (A) The concentration of JNK1/2-siRNA that efficiently
repressed JNK1 and JNK2 expression was determined at 48 h by Western blot
analysis using JNK1 and JNK2 selective antibodies. (B) The effect of JNK1/2115

siRNA upon cell viability was assessed using crystal violet staining. Statistical
analysis was performed by one-way ANOVA using Tukey’s post-test for multiple
comparisons. (C) The effect of JNK1/2-siRNA upon Ad replication was assessed
via the TCID50 method. Statistical analysis was performed by one-way ANOVA
using Tukey’s post-test for multiple comparisons. † indicates p-value < 0.01, ‡
indicates p-value < 0.001.
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4.4 – Discussion
The goal of the studies in this chapter was to ascertain the relationship
between Ads, p-JNK, Ad replication and oncolysis. Other laboratories have
reported the requirement of JNK expression for the oncolytic effects of the E1bwild-type oncolytic Ad, Δ24RGD [81]. These findings were studied further by
observing the effect of E1b upon JNK, specifically to understand why E1bdeleted Ads produced disappointing results during clinical trials and to determine
if p-JNK inducers can enhance the efficacy of Ad therapy. To my knowledge, this
is the first report demonstrating the role of JNK to promote both Ad replication
and oncolysis.
During Ad infection, many cell death pathways are induced. However,
several reports agree that autophagy is the predominant mechanism of cancer
cell death induced following oncolytic Ad infection [55, 66, 78, 162-164]. In this
report, significant induction of the autophagy marker LC3-II in A549 cells was
observed following wild-type Ad5 infection beginning at 36 h post-infection
(Figure 13C). The expression of p-JNK is known to induce autophagy via the
phosphorylation

of

BCL-2,

releasing

BECLIN-1,

which

then

initiates

autophagosome formation [88, 151, 164]. Attenuated p-JNK induction by E1bdeleted Ads was most pronounced following E1b55,19K-deleted Ad Adhz60
infection relative to the E1b55K-deleted Ad Adhz63; indicating the importance of
E1b-19K as a p-JNK inducer (Figure 15B). This finding is consistent with the only
other known report describing E1b-mediated JNK phosphorylation [80]. In this
study, E1b-19K was shown to be the main driver of JNK phosphorylation [80].
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This finding was confirmed using a selective E1b-19K expressing plasmid known
as CMV-E1b19K [158]. These data indicated E1b-19K alone was sufficient to
induce p-JNK production in A549 cells (Figure 15E).
However, the E1b55,19K-deleted Ad Adhz60 induced p-JNK during Ad
infection despite the loss of E1b, implicating the role of other non-E1b genes
such as E1a to induce JNK phosphorylation (Figure 15B). Therefore, the
E1b55K-deleted, CMV-E1a Ad Adhz69 [157] which overexpresses E1A was
used to determine if increased E1A production stimulates greater JNK
phosphorylation. These data indicated that E1a overexpression led to a marked
increase in p-JNK production in A549 cells (Figure 16B). This is the first report, to
my knowledge, to indicate that E1A induces JNK phosphorylation in cancer cells.
To test if increased E1A production indirectly enhanced the expression of E1b19K, A549 cells were infected with Ad5, Adhz63, Adhz60, and Adhz69 and
observed for the production of E1b-19K by Western blot analysis. These data
indicated that Adhz69 displayed slightly greater levels of E1b-19K production
(31.0 IOD) than the E1b55K-deleted Adhz63 (20.1 IOD; Figure 16B,C).
Considering the subtle differences shown in E1b-19K expression, it is likely that
the markedly enhanced p-JNK induction following Adhz69 treatment was due to
increased E1A and not E1b-19K production. E1A, much like E1b-19K, does not
have any endogenous kinase activity therefore it is likely that E1A induces JNK
phosphorylation by the stimulation of the MAPK cascade or another family of
kinases during infection. The effect of E1A upon JNK phosphorylation will be the
subject of future studies.
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Due to the important role of p-JNK during Ad oncolysis, cancer
chemotherapeutics were screened for p-JNK production and observed their
effects upon AdUV replication and oncolysis; AdUV was developed and
characterized as described previously [82, 136]. These data indicated that
etoposide was the greatest inducer of p-JNK production and was also shown to
significantly enhance Ad oncolysis (p-value < 0.001; Figure 17C). For the first
time, these data indicated that cancer chemotherapeutic drugs inducing p-JNK
could enhance the therapeutic efficacy of oncolytic Ads.
The use of pharmacological JNK phosphorylation inducers likely
stimulated an array of other signaling pathways in addition to JNK, therefore
additional approaches were necessary to further elucidate the effects of JNK
upon Ad replication and oncolysis. To determine the effect of JNK upon Ad
replication and oncolysis selectively, A549 cells were transfected with siRNA
targeting identical mRNA sequences contained in both JNK1 and JNK2 mRNA
[155, 156]. JNK1/2-siRNA transfected cells were shown to be partially protected
against Ad-mediated A549 cell lysis (Figure 19B). These effects were more
pronounced in the Ad5 and Adhz63 treatment groups. Ad5, Adhz63 and Adhz60
replication was also suppressed in JNK1/2-siRNA relative to scramble-siRNAtransfected cells. These data indicate the critical role of JNK to enhance Ad
oncolysis and replication.
In addition to inducing autophagic cancer cell death, p-JNK can also
induce cancer cell growth. For example, A549 cells treated with the JNK1/2/3
inhibitor, sp600125, were shown to form significantly smaller tumors in nude mice
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[165]. A549 cells are known to express k-RAS; the RAS pathway phosphorylates
JNK indirectly via MKK7 of the MAPK cascade [166]. Unfortunately, there are
very limited molecular tools to observe the selective effects of p-JNK upon
autophagy without disrupting other important cellular processes such as cancer
cell growth which play a significant role during Ad replication. Ads induce the
cyclin E/CDK2 axis to induce an S-phase-like state in G0 cells during infection,
increasing DNA synthesis in order to replicate Ad DNA [31, 33]. It is possible,
therefore, that the inhibition of oncolytic Ad efficacy following JNK1/2-siRNA
transfection could be the result of A549 cell cycle repression and not a direct
effect of JNK upon Ad oncolysis.
These studies indicated for the first time that JNK not only supports Ad
oncolysis, but also Ad replication. These data also indicate that Adhz69, an E1b19K wild-type E1a over-expressing Ad, was a highly efficient inducer of p-JNK
production, implicating that E1A may play a significant role to induce JNK
phosphorylation (Figure 16B). Cancer chemotherapeutics inducing p-JNK were
also shown to enhance Ad oncolysis, supporting the role of p-JNK to enhance Ad
oncolytic therapy (Figure 17C and 18A). The role of JNK to support Ad oncolysis
were confirmed using JNK1/2-targeting siRNA; JNK suppression was also shown
to inhibit Ad replication (Figure 19B,C). Previous reports indicate that autophagy
inducers supported Ad oncolysis and replication [55, 66]. I have extended upon
these studies and these data implicate p-JNK as an intriguing molecular target to
enhance the cancer therapeutic efficacy of oncolytic Ads.
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CHAPTER V
SUMMARY AND FUTURE PERSPECTIVES

All clinical studies conducted to date have shown that the efficacy of Ad
oncolytic virotherapy has remained low [15, 17, 18, 57, 58, 98-100]. The
disappointing efficacy of oncolytic Ads tested clinically appears to be due to
many factors, including limited cancer cell lysis, inefficient Ad release from
cancer cells, and spread in tumors [101-103]. Progress to improve the antitumoral effects of Ads has been hampered by a lack of knowledge pertaining to
which gene and mutations lead to enhanced Ad release and spread.
Furthermore, the molecular mechanisms by which E1b-deleted oncolytic Ads
induce oncolysis, specifically via autophagy and JNK phosphorylation are
unknown. My goal was to fill these gaps and to obtain valuable information to
enhance the cancer therapeutic efficacy of oncolytic Ads.
Previously, oncolytic Ad spread was shown to be limited in solid tumors
[35]; oncolytic Ads were shown to only infect of 5-20 tumor cells around the
injection site following intratumoral injection [103]. In this dissertation, the
oncolytic Ad mutant (AdUV) was developed. AdUV displayed enhanced release
and spread. Upon DNA analysis, mutations which may have been responsible for
enhanced AdUV release and spread may have been identified. These DNA
mutations will be the subject of future experimentation. This dissertation also
presents data extending the mechanistic understanding by which E1b-deleted
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Ads phosphorylate JNK. Additionally the p-JNK inducer, etoposide, was shown to
enhance the oncolytic effects of AdUV in vitro.
Initial studies, shown in Chapter II, focused upon the development and
characterization of the novel oncolytic Ad AdUV. Most Ads used in clinical
studies have been subjected to E1 gene modifications to produce cancer
selective Ad vectors. E1b-deleted Ads were shown to display attenuated
oncolytic Ad replication, suppressing their therapeutic efficacy [96]. An alternative
strategy to develop oncolytic Ads is to use random DNA mutagenesis and then
select for Ad mutants with the desired therapeutic properties. In this dissertation,
the E1 wild-type Ad, dl309 (Ad5) was repeatedly UV irradiated and selected in
Soas-2 cells for 72 cycles. AdUV was then isolated from a large plaque clone
formed on Soas-2 cells. After the characterization of 6 Ad large plaque forming
clones, AdUV was shown to lyse cancer cells with the greatest efficiency and
was studied further. AdUV was characterized and shown to lead to more efficient
oncolysis compared to Ad5. This appeared to be related to enhanced autophagy
induction and viral spread in vitro. (This paper has been published in Viruses
2016, 8(6), 167; doi: 10.3390/v8060167).
The work presented in Chapter III focused upon the investigation of those
mutated genes in the AdUV genome. These mutations were thought to alter Ad
oncolytic efficacy and therefore may be integrated into novel Ad vectors or
combined with other approaches to develop next generation novel oncolytic Ads
with enhanced cancer therapeutic efficacy. The Ad early genes in AdUV, E1a
and E1b, E2, and E4, remained unchanged, however, the Ad late genes were
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mutated. The mutations occurring within pV and its interaction partners IVa2 and
pVIII, indicating the importance of these DNA packaging proteins for Ad
oncolysis. Indirect evidence suggests that IVa2 and 33K can also form a complex
with DNA-binding protein (DBP) on the 12 Ad capsid vertexes, facilitating Ad
DNA packaging [110]. Additional mutations to pV and 52K also appear to have
enhanced Ad DNA packaging via increasing the number of positively charged
amino acids in these DNA binding proteins. To characterize the impact(s) of
these mutations upon Ad replication and oncolysis, furher studies are needed to \
incorporate them into an Ad vector with well-characterized cancer selectivity.
Additionally, the work presented in Chapter III indicated that AdUV
suppressed A549 xenograft tumor growth and was non-lethal in nude mice.
AdUV is an E1b wild-type Ad. E1b wild-type Ads displayed limited cancer
therapeutic efficacy previously [138]. Therefore, the goal of this limited animal
study to investigate whether these novel AdUV mutations were toxic to A549xenograft-bearing athymic nude mice (NCr-nu/nu). It is possible that the
expression of E1b by AdUV could have also contributed to its enhanced oncolytic
effects. Several other E1b wild-type oncolytic Ad vectors have been reported to
display increased cancer therapeutic efficacy [81, 130]. Even though E1b
expression is not essential for Ad replication in cancer cells [31], E1b may
enhance Ad replication efficiency in cancer cells, likely via the induction of
cyclinE [31] and autophagy [66]. Previously, E1b was shown to induce autophagy
to provide the necessary macromolecules to promote Ad replication and
oncolysis [55, 66]. Therefore the effects of these mutations upon autophagy, as
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well as the investigation of the interactions of Ads with autophagy mediators, may
reveal additional therapeutic approaches to enhance oncolytic Ad therapy (This
paper has been published in Viruses 2016, 8(12), 333; doi: 10.3390/v8120333).
Chapter IV built upon the initial studies shown in Chapters II and III by
evaluating p-JNK induction by E1b-deleted Ads in A549 cells. These studies also
investigate the impact of p-JNK upon Ad replication and oncolysis. Previously pJNK was reported as an essential cellular factor for the oncolysis of E1b wildtype Ads [88]; therefore the effect of JNK expression upon the replication and
oncolysis of E1b wild-type and E1b-deleted Ads in A549 cells was evaluated via
JNK1/2-siRNA suppression. These siRNA-JNK1/2 suppression studies indicated
that JNK enhanced Ad replication and oncolysis in A549 cells. E1b-deleted Ads
also displayed less p-JNK production in A549 cells. These differences were most
pronounced between the E1b55K-deleted Adhz63 and the E1b55,19K-deleted
Adhz60, indicating the importance of E1b-19K as a p-JNK inducer. This finding
was validated using an E1b-19K plasmid expression vector. It also appears that
the expression of E1A led to JNK phosphorylation. Increased E1a-mediated E1b19k transactivation may also play a minor role to induce p-JNK production as
observed by Western blot analysis (This manuscript is in preparation).
The work presented in this dissertation has addressed the question, “How
can oncolytic Ad virotherapy be enhanced?” by generating a novel oncolytic Ad
(AdUV) with enhanced anticancer efficacy, revealed DNA mutations which
potentially could be utilized to create the next generation of oncolytic Ads, and
provided a deeper understanding of how Ads induce the JNK pathway with
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implications for novel combinatorial cancer therapeutic development. This work
also raises a number of interesting directions for future research in the field of
oncolytic virotherapy.
First, there is still much more to learn about the mutations and oncolytic
properties of AdUV. These data indicate that AdUV contained several DNA
mutations which may have contributed to its enhanced oncolytic efficiency,
enhanced autophagy induction and release from A549 cells in vitro. DNA
sequence analysis indicated that most of these mutations occurred in the Ad late
genes, implicating their significance for the development of future oncolytic Ads.
To determine which mutation(s), or combination of mutations, have the greatest
effect upon oncolysis, additional in vitro and in vivo studies are necessary.
Second, AdUV effectively suppressed A549 xenograft tumor growth while
remaining non-lethal to athymic nude mice (NCr-nu/nu). Twelve of these
mutations were shown to alter their respective encoded amino acid sequences.
Six of these mutations were shown to occur in genes associated with Ad DNA
packaging (Iva2, pTP, 33K, pV, 52K and pVIII). Two of these mutations, 52K and
pV, replaced their encoded amino acids for positively charged residues.
Therefore, I hypothesized that these mutations increased the ability of 52K and
pV to bind the negatively charged DNA sugar-phosphate backbone more
efficiently, leading to more rapid Ad release from infected cancer cells. I propose
to incorporate these 52K and pV mutations into the E1b-deleted, cyclin E
promoter driven E1A Ad, Ad-cycE as described previously [34, 35, 55]. These
mutations must be incorporated into an E1b-deleted background because the
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wild-type Ad5 was shown to be in-effective during clinical trials for cervical cancer
in the 1950’s [138]. In addition to their limited anti-cancer efficacy, E1 wild-type
Ads are no longer used in clinical studies due to their safety concerns and
potential for cancer non-selective replication. For these reasons, E1 wild-type
Ads such as AdUV are unlikely to be used in future clinical studies; however by
the inclusion of these mutations into E1b-deleted vectors, such as Ad-cycE, the
effects of these mutations can be further characterized and potentially be
translated clinically.
Third, the role of E1b-19K and E1a as inducers of JNK phosphorylation
was elucidated in A549 cells. Interestingly, E1a-induced p-JNK may also be
related to E1b19K via E1a-mediated, E1b-19K transactivation [40, 160]. Previous
reports indicated that E1a alone was not sufficient to induce p-JNK production
[80]. Therefore, the effects of E1a upon p-JNK in the absence of E1b-19K as well
as the effects of E1a and E1b-19K plasmid co-transfection will be the subject of
future studies.
E1A effects many cellular pathways, however one of its most crucial roles
is as a master regulator of viral and host cell gene transactivation. In this manner,
E1A manipulates many cellular pathways to enhance Ad replication. It is also
possible that E1A induces p-JNK by binding retinoblastoma protein (pRb),
displacing the transcription factor E2F-1 from its pRb binding pocket, which then
transactivates the expression of many autophagy-related genes including LC3
and BECLIN-1 [167-169]. Another transcription factor modulated by E1a is p300.
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p300 has been shown to form a multiprotein complex with CREB binding protein
(CBP) and cyclic AMP dependent transcription factor (ATF2) protein to
specifically bind the JUN2 element [170]. E1b wild-type Ads also induce
autophagy independently of c-JUN expression [88]. This observation may be
reconciled by the observation that JNK target sites on ATF2 were not required for
the formation of the p300/CBP-ATF2 multi-protein complexes, indicating that pJNK and p300 act independently to induce c-JUN and autophagy [170]. JNK also
participates in c-JUN-induced gene transactivation [171]. Therefore, it is also
possible that p-JNK can enhance Ad gene transactivation in cooperation with cJNK to enhance Ad replication. In future studies, microarray and Ad serotype 5
genomic analyses could identify novel c-JUN DNA binding sites to predict which
Ad genes are affected by increased p-JNK production in cancer cells.
To further understand the effect of p-JNK upon Ad replication and
oncolysis, the use of chemical p-JNK inducers and siRNA mediated JNK
suppression were utilizied. Etoposide was shown to induce p-JNK and enhance
oncolysis, while inhibiting Ad replication. Another p-JNK inducer cycloheximide,
was inhibited Ad oncolysis or replication of AdUV. I hypothesize these effects
upon Ad replication may be related to the apoptosis induction by etoposide and
the inhibition of protein synthesis by cycloheximide respectively [172]. These
cancer chemotherapeutic drugs therefore may act upon p-JNK via a nonselective mechanism of action. Therefore A549 cells were subjected to JNK1/2
siRNA-mediated suppression. These data indicated that JNK enhanced AdUV
oncolysis and replication. It is clear that p-JNK expression supports Ad
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replication and oncolysis, but the effects of JNK upon c-JUN, the transactivation
of Ad genes and the licensing DNA replication machinery remains an interesting
area for future research.
These data indicate that p-JNK inducers are attractive molecular targets to
enhance the anti-cancer therapeutic efficacy of oncolytic Ads. Another intriguing
molecular target which has not been studied is the JNK phosphatase M3/6. M3/6
selectively de-phosphorylates JNK; therefore, the inhibition of M3/6 would likely
significantly enhance p-JNK production in a much more selective manner than
cancer chemotherapeutics utilized in this study. The Dr. McMasters laboratory
has confirmed that autophagy inducers acting via the cell starvation pathway
enhanced oncolytic Ad replication and oncolysis. However these studies shown
in Chapter IV indicate that autophagy inducers acting upon the p-JNK/BECLIN-1
axis would produce greater synergistic cancer cell killing effects in combination
with E1b-deleted oncolytic Ads than drugs targeting cell starvation induced
autophagy [55, 66].
These studies taken together have characterized the novel oncolytic Ad,
AdUV, which displayed the therapeutic properties of enhanced oncolysis,
release, spread and autophagy induction. Following DNA sequence analysis, the
ability of AdUV to induce its enhanced cancer therapeutic effects appears related
to mutations in the Ad late genes, specifically genes associated with Ad DNA
packaging. This dissertation also provided a more complete description of the
interaction between the E1 genes, JNK and Ad oncolysis. For the first time, a link
between JNK expression and Ad replication in cancer cells using JNK1/2128

targeting siRNA. There are many exciting future directions of these studies,
including: the incorporation of AdUV DNA packaging gene mutations into well
characterized oncolytic Ad vectors, the effect of JNK upon cyclin E, determining
whether JNK is required for Ad-mediated DNA replication licensing, and finally,
whether selective JNK induction enhances E1b-deleted Ad oncolysis. I believe
that future progress in oncolytic adenovirology, along with various improvements
in targeted therapeutic strategies, should pave the way for the next generation of
oncolytic virotherapy.
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APPENDIX
List of Abbreviations
3MA

3-methyladenine

Ad

Adenovirus

Ad2

Adenovirus serotype 2

Ad5

Adenovirus serotype 5

Ads

Adenoviruses

AEBSF

4-(2-aminoethyl)-benzenesulfonyl fluoride

AMPK

AMP-activated protein kinase

ANOVA

Analysis of Variance

AKT

Protein Kinase B

ATF2

Cyclic AMP Dependent Transcription Factor

Atg

Autophagy related

BAL

Bronchoalveolar Lavage

CFDA

China Food and Drug Administration

ddH20

Double Distilled Water

DMEM

Dulbecco’s Modified Eagle Medium

E1A

Early gene 1 A
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E1B

Early gene 1 B

EC50

Effective Concentration 50%

ECL

Enhanced Chemiluminescence

FBS

Fetal Bovine Serum

FDA

Food and Drug Administration

GFP

Green Fluorescent Protien

HRP

Horse Radish Peroxidase

IFU

Infectious Viral Unit

Ig

Immunoglobin

IGV

Integrated Genomics Viewer

IT

Intratumoral injection

IV

Intravenous injection

LB

Luria-Bertani broth

LC3

Light Chain 3

MAPK

Mitogen Activated Protein Kinase

MOI

Multiplicity of Infection

OD

Opitical Density or absorbance

IOD

Integrated Optical Density

PBS

Phosphate Buffered Saline
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PFU

Plaque Forming Units

PI3K

Phosphoinositide 3-Kinase

PI

Protease Inhibitor

PML-nb

Promyelocytic Leukemia ProteinNuclear Bodies

RCF

Relative Centrifugal Force

RIPA

Radioimmunoprecipitation Assay Buffer

RPM

Revolutions Per Minute

RPMI

Roswell Park Memorial Institute

SC

Subcutaneous injection

SDS

Sodium Dodecyl Sulfate

SEER

Surveillance Epidemiology and End Results

Ser

Serine

TBST

Tris-Buffered saline with Tween 20

TNM

Tumor Nodes Metastatsis

Wt

Wild-type
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Wechman SL, Rao XM, Cheng PH, McMasters KM, Zhou HS. 2016. Improved Oncolytic
Virotherapy by Increasing Adenovirus Spread. Poster # 3753, American Association for
Cancer Research, Gene and Vector-Based Therapy section, New Orleans, Louisiana .
Local/Regional Meetings
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1.

Wechman SL, and Garcia-Ramos G. 2011. Comparisons of inhibitory techniques against
HIV-1 using recombinant viruses. Kentucky Academy of Sciences, Cellular and Molecular
Biology section, Murray, Kentucky.

2.

Wechman SL, Rao XM, Cheng PH, Hao H, Gomez-Gutierrez JG, McMasters KM, Zhou
HS. 2012. Insights from novel UV mutant oncolytic E1b-deleted adenoviruses for cancer
gene therapy. Research! Louisville, Louisville, Kentucky.

3.

Wechman SL, Rao XM, McMasters KM, Zhou HS. 2013. AdUV has greater potency,
replication, and spread within lung cancer cells. Research! Louisville, Louisville,
Kentucky.

4.

Wechman SL, Rao XM, McMasters KM, Zhou HS. 2013. AdUV has greater potency,
replication, and spread within lung cancer cells. Brown Cancer Center Retreat, Louisville,
Louisville, KY.

5.

Wechman SL, Rao XM, McMasters KM, Zhou HS. 2014. AdUV has greater potency,
replication, and spread within lung cancer cells. Research! Louisville, University of
Louisville, Louisville, Kentucky.

6.

Gao H, Rao XM, Wechman SL, McMasters KM, Zhou HS 2014. Viability of losartan and
other anti-fibrotics in combination with oncolytic adenovirus therapy. Research! Louisville,
University of Louisville, Louisville, Kentucky.

7.

Wechman SL, Rao XM, McMasters KM, Zhao HS 2014. AdUV has greater potency,
replication, and spread within lung cancer cells. James Graham Brown Cancer Center
Retreat, University of Louisville, Louisville, Kentucky.

8.

Gao H, Rao XM, Wechman SL, McMasters KM, Zhao, HS. 2014. Viability of losartan and
other anti-fibrotics in combination with oncolytic adenovirus therapy. James Graham
Brown Cancer Center Retreat, University of Louisville, Louisville, Kentucky.

9.

Wechman SL, Rao XM, Cheng PH, McMasters KM, Zhou HS. 2015. Improvement of
Oncolytic Adenovirus efficacy via bioselection. Research Louisville, University of
Louisville, Louisville, Kentucky.

10.

Nitz J, Wechman SL, Reidinger E, Sharma R, Zhou HS, McMasters KM, GomezGutierrez JG. 2015. Combined Therapy of Oncolytic Adenovirus and Temozoloamide
Enhances Lung cancer virotherapy in vitro and in vivo. Research! Louisville, University of
Louisville, Louisville, Kentucky.

11.

Kemper N, Rao XM, Wechman SL, Zhou HS, McMasters KM. 2015. I3C Decreases
Cyclin E expression and represses cancer cell growth. Research! Louisville, University of
Louisville, Louisville, Kentucky.

12.

Wechman SL, Rao XM, Zhou HS, McMasters KM. 2016. Improvement of Oncolytic
Adenovirus Efficacy via Repeated UV-Irradiation and Cancer Selection. Research!
Louisville, University of Louisville, Louisville, Kentucky.

13.

Wechman SL, Rao XM, Zhou HS, McMasters KM. 2016. Improvement of Oncolytic
Adenovirus Efficacy via Repeated UV-Irradiation and Cancer Selection. Kentucky Lung
Cancer Research Program (KLCR). University of Kentucky, Lexington, Kentucky.
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Published manuscripts
1.

Cheng PH, Wechman SL, McMasters KM, Zhou HS. 2015. Review. Oncolytic replication
of E1b-deleted Adenoviruses. Viruses. 7(11):5767-5779. DOI: 10.3390/v7112905

2.

Gomez-Gutierrez JG, Nitz J, Sharma R, Wechman SL, Riedinger E, Martinez-Jaramillo
E, Zhao HS, McMasters KM. 2015. Combined Therapy of Oncolytic Adenovirus and
Temozolomide Enhances Lung Cancer Therapy in vitro and in vivo. Virology. 487:249259. DOI: 10.1016

3.

Cheng PH, Rao XM, Wechman SL, McMasters KM, Zhou HS. 2015. Oncolytic
Adenovirus Targeting Cyclin E Overexpression Repressed Tumor Growth in Syngeneic
Immunocompetent Mice. BMC Cancer. 15(1):716-727. DOI: 10.1186/s12885-015-1731-x

4.

Wechman SL, Rao XM, Cheng PH, Gomez-Gutierrez JG, McMasters KM, Zhou HS.
2016. Development of an Oncolytic Adenovirus with Enhanced Spread Ability Through
Repeated
UV
Irradiation
and
Cancer
Selection.
Viruses.
8(6):167-181.
DOI:10.3390/v8060167

5.

Wechman SL, Rao XM, McMasters KM, Zhou HS. Adenovirus with DNA Packaging
Gene Mutations Increased Virus Release. Viruses 2016, 8(12), 333 doi:10.3390/v812033

Submitted Manuscripts
1.

Martinez-Jaramillo E*, Wechman SL*, Shirwan H, Montes-de-Oca-Luna R, Zhou HS,
McMasters KM, Gomez-Gutierrez JG. Adenovirus lacking E1b efficiently induces
cytopathic effect in HPV-16-positive murine cancer cells via virus replication and
apoptosis. Submitted to Cancer Investigation.
(Note: * denotes equal contribution to the manuscript)

Manuscripts in progress
1.

Wechman SL, Rao XM, McMasters KM, Zhou HS. DNA sequence analysis of a mutant
oncolytic adenovirus displaying enhanced cancer cell lysis.

2.

Wechman SL, Rao XM, McMasters KM, Zhou HS. The Role of JNK Phosphorylation as
a Molecular Target to Enhanced Adenovirus Replication, Oncolysis and Cancer
Therapeutic Efficacy.

PANEL DISCUSSIONS
1.

Invited speaker, “Interested in graduate school?” a panel discussion for current
Georgetown College Students. Georgetown College,
Georgetown, KY, September
27, 2012. (Inviter: Dr. Tim Griffith, Associate Professor)

2.

Inviter speaker, Panel discussion about the transition between Undergraduate and
Graduate school for current Virginia State University Students. Virginia State University,
Richmond, VA, April, 5, 2017. (Inviter: Dr. Leslie Whiteman, Associate Professor)

COMMUNITY SERVICE
Member, Newtown Christian Church, Choir (2005-2011)
Deacon, Newtown Christian Church (2010-2011)
Head Deacon, Newtown Christian Church (2010)
Judge, Louisville Regional Science & Engineering fair, Junior Biomedical sciences division (2016)
Volunteer, Splat Out Cancer, University of Louisville James Graham Brown Cancer Center (2016)
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SKILLS
Lab skills:
Cell culture, western blot analysis, DNA transfection, bacterial transformation, DNA digestion,
level 2 animal training (mice), intratumoral injection, subcutaneous injection, intraparenteral
injection, tail vein injection, microtome based frozen tissue sectioning, H&E staining,
immunohistochemistry, handling and propagation adenoviruses, DNA sequence analysis, cancer
cell cloning, CRISPR/Cas9 gene editing technology and statistical analysis (trained by Dr. Shesh
N. Rai, director of biostatistics at UofL).
Computer skills:
Advanced knowledge of excel spreadsheet and forumula manipulation, word, powerpoint,
western blot densitometry, Graphpad Prism, Integrated genomics viewer (IGV), ImageJ, Gelpro
3.2, calcusyn, Gel pro analyzer 4.0, and math models using differential equations and MATLAB.
Soft skills:
Skilled presenter (5 awards / 8 attempts = 62.5%), excellent interpersonal verbal communication
skills, lecturer (12 lectures), and experienced student mentor (11 summer students).
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